---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence. Covers FORTIFI-HN01, BCA101X1101, and FORTIFI-FLEX. 195 evidence topics quoted from 31 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence

<a id="clinical-evidence"></a>

## 3 Clinical Evidence

<a id="heading-3.1"></a>

### 3.1 Study Summaries

<a id="heading-3.1.1"></a>

#### 3.1.1 FORTIFI-HN01

<a id="heading-3.1.1.1"></a>

##### 3.1.1.1 Objective

<a id="topic-3.1.1.1-1"></a>

###### Study purpose in the ClinicalTrials.gov record

> “This study intends to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab versus placebo with pembrolizumab in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).”
> “The primary objective for the phase 3 portion is to compare the efficacy in subjects treated with ficerafusp alfa at the selected OBD in combination with pembrolizumab versus placebo with pembrolizumab.”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.1-2"></a>

###### Phase 2 and phase 3 objectives in the EU trial record

> “Assessing safety and tolerability of ficerafusp alfa in participants randomized to ficerafusp alfa 1500 mg once weekly (QW) with pembrolizumab (Treatment Arm A) and ficerafusp alfa 750 mg QW with pembrolizumab (Treatment Arm B).”
> “Assessing antitumor activity of ficerafusp alfa in participants randomized to ficerafusp alfa 1500 mg QW with pembrolizumab (Treatment Arm A) and ficerafusp alfa 750 mg QW and pembrolizumab (Treatment Arm B).”
> “To compare efficacy in participants treated with ficerafusp alfa at the selected OBD in combination with pembrolizumab versus placebo plus pembrolizumab.”
> “Phase 3 secondary: To compare safety and tolerability of participants treated with ficerafusp alfa at the selected OBD in combination with pembrolizumab versus placebo plus pembrolizumab.”
> “Phase 3 secondary: To evaluate time to deterioration (TTD) in global health status/quality of life and pain in participants treated with ficerafusp alfa in combination with pembrolizumab versus placebo plus pembrolizumab.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.1-3"></a>

###### Study question in the updated trial-in-progress poster

> “FORTIFI-HN01 (NCT06788990) is a Phase 2/3 study designed to investigate whether first-line (1L) treatment with ficerafusp alfa plus pembrolizumab improves objective response rate (ORR) and OS vs pembrolizumab alone in patients with HPV-negative, PD-L1–positive, R/M HNSCC”

Source: [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf)

<a id="heading-3.1.1.2"></a>

##### 3.1.1.2 Location and Study Date

<a id="topic-3.1.1.2-1"></a>

###### Study dates and sites in the ClinicalTrials.gov record

| Study characteristic | Quoted record |
| --- | --- |
| Study start (actual) | “2025-01-28” |
| Primary completion (estimated) | “2028-04” |
| Study completion (estimated) | “2029-07” |
| Sites | “This study has 231 locations” |

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.2-2"></a>

###### Enrollment regions in the updated trial-in-progress poster

> “FORTIFI-HN01 is open to enrollment at sites in North America, South America, Europe, Asia, and Oceania”

Source: [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf)

<a id="topic-3.1.1.2-3"></a>

###### First enrollment in the annual report

> “We enrolled the first patients in the FORTIFI-HN01 trial in February 2025.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="heading-3.1.1.3"></a>

##### 3.1.1.3 Study Design

<a id="topic-3.1.1.3-1"></a>

###### Seamless phase 2 and phase 3 design in the ClinicalTrials.gov record

> “A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma”
> “Phase 2 of the study will identify an optimal biologic dose (OBD) supported by the safety, tolerability, PK, PD, and efficacy data of ficerafusp alfa. In this part, eligible subjects will be randomized to one of three treatment arms at a 1:1:1 ratio:”
> “Eligible subjects will be randomized 2:1 in the treatment versus control arm during the phase 3 portion.”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.3-2"></a>

###### Blinding in the EU trial record

> “Treatment will be blinded to subjects, investigator staff, persons performing the assessments, and the clinical study team.”
> “Once the OBD is determined, additional subjects will be randomized 2:1 in the treatment versus control arm.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.3-3"></a>

###### Stratification factors in the updated trial-in-progress abstract

> “Following OBD determination (1500 mg QW), the trial transitioned seamlessly into the phase 3 portion with 2:1 randomization (ficerafusp alfa:control).”
> “Randomization is stratified by PD-L1 CPS (1-19 vs ≥20) and disease extent (local/regional recurrence only, distant metastasis only, or both).”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

<a id="topic-3.1.1.3-4"></a>

###### Phase 2 dose decision rule in the initial trial-in-progress poster

> “Phase 2: OBD decision”
> “After 10-20 patients per arm have ≥12 weeks of follow-up”

Source: [Ferrarotto et al. (2025b)](https://www.bicara.com/wp-content/uploads/2025/06/FINAL_Bicara_ASCO_TiP_Poster-1.pdf)

<a id="topic-3.1.1.3-5"></a>

###### Dose optimization run-in in the annual report

> “As seen below, this registrational trial is designed with a dose selection run-in consistent with the objectives of the FDA’s Project Optimus.”
> “The Phase 2 portion of the FORTIFI-HN01 trial was a dose optimization run-in that randomized patients 1:1:1 to receive either 1500mg QW of ficerafusp alfa in combination with pembrolizumab, 750mg QW of ficerafusp alfa in combination with pembrolizumab, or placebo plus pembrolizumab.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-3.1.1.3-6"></a>

###### FDA dose-optimization guidance on randomized dose comparison

> “A recommended trial design to compare multiple dosages is a randomized, parallel dose-response trial.”
> “When a registration trial contains multiple dosages and a control arm and is designed to establish superior efficacy of one of the dosages compared to the control arm, the trial design should provide strong control of Type I error.”

Source: [FDA (2024)](https://www.fda.gov/media/164555/download)

<a id="heading-3.1.1.4"></a>

##### 3.1.1.4 Eligibility Criteria

<a id="topic-3.1.1.4-1"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

> “Age ≥18 years on the day the Informed Consent Form is signed.”
> “Histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: primary tumor location of paranasal sinuses and nasopharynx, any histology are excluded.”
> “No prior systemic therapy administered in the R or M setting; and completed systemic therapy >6 months prior if given as part of multimodal treatment for locoregionally advanced disease in the adjuvant or definitive setting.”
> “Archival tumor tissue or willing to undergo pretreatment biopsy at Screening if archival tissue is insufficient or unavailable.”
> “PD-L1 CPS ≥1.”
> “Measurable disease based on RECIST 1.1.”
> “Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.”
> “Adequate organ function, as defined in the protocol.”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.4-2"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “Disease suitable for local therapy administered with curative intent.”
> “Prior treatment with anti-TGFβ therapy.”
> “Prior therapy with an anti-EGFR antibody (exception: radio sensitizing agents and multimodal treatment for locoregionally advanced disease).”
> “Prior history of Grade ≥2 intolerance or hypersensitivity reaction to anti-EGFR therapy or other murine proteins.”
> “Prior therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.”
> “Progressive disease <6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.”
> “Life expectancy less than 3 months.”
> “Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or leptomeningeal disease are excluded.”
> “Current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.”
> “Subject participated in another clinical study or received treatment with another investigational drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy.”
> “Active autoimmune disease requiring systemic treatment in the past 2 years.”
> “Subjects with chronic hepatitis B virus (HBV) infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment.”
> “Subjects with a known history of hepatitis C virus (HCV) who have not completed curative antiviral treatment or have an HCV viral load above the limit of quantification at Screening.”
> “Known history of human immunodeficiency virus (HIV).”
> “Receipt of any organ transplantation, including autologous and allogeneic stem cell transplantation, with the exception of transplants that do not require immunosuppression.”
> “Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer.”
> “Any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids.”
> “Use of a live or live attenuated vaccine within 4 weeks prior to Screening.”
> “Other Inclusion/Exclusion criteria may apply as defined in the protocol.”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.4-3"></a>

###### Primary site and histology in the EU trial record

> “Participant has histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: Primary tumor location of paranasal sinuses and nasopharynx, or tumor of any other histology are excluded.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.4-4"></a>

###### HPV status determination in the EU trial record

> “Participant has documentation of HPV-negative disease per central testing performed if presenting with OPSCC. Tumor tissue from excisional/incisional or core biopsy (fine needle aspirates and bone biopsies are not acceptable) must be provided for central testing. Archival tumor tissue is acceptable. A fresh tumor biopsy, using a procedure that is safe for the participant on a lesion not previously irradiated (unless lesion progressed) will be required if tumor tissue is not available. Note: To be eligible to participate in this study, participants with OPSCC must have HPV-negative documentation.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.4-5"></a>

###### HPV assay developer named in the EU trial record

| Third party | Quoted record |
| --- | --- |
| Organization | “Qiagen Manchester Limited” |
| Duty delegated by the sponsor | “Development of HPV DNA Assay” |

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.4-6"></a>

###### PD-L1 assay and testing in the EU trial record

> “Participant is eligible to receive pembrolizumab as frontline monotherapy with documented tumor PD-L1 CPS ≥1 (PD-L1 immunohistochemistry [IHC] via 22C3). If appropriate local documentation of PD-L1status is not available, tumor tissue from excisional or core biopsy (fine needle aspirates and bone biopsies are not acceptable) must be provided for central testing to determine eligibility.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.4-7"></a>

###### Prior-therapy criteria in the EU trial record

> “No prior systemic therapy administered in the R or M setting. Systemic therapy completed >6 months prior to signing ICF if given as part of multimodal treatment for locoregionally advanced disease is allowed.”
> “Prior systemic therapy in the R or M setting.”
> “Prior treatment with anti-TGF-β therapy.”
> “Prior therapy with an anti-EGFR antibody.”
> “Prior history of Grade ≥2 intolerance or hypersensitivity reaction.”
> “Prior (neoadjuvant and/or adjuvant) therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.”
> “PD (radiologically or pathologically confirmed) <6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.4-8"></a>

###### Measurable disease, performance status, and age in the EU trial record

> “Participant has measurable disease based on RECIST 1.1 as determined by BICR. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated. Baseline Scan must be transferred to BICR for assessment.”
> “Participant has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.”
> “Participant is >18 years of age or of an acceptable age according to local regulations, whichever is older on the day the ICF is signed.”
> “Life expectancy of less than 3 months and/or has rapidly progressing disease in the treating investigator's opinion.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.4-9"></a>

###### Bleeding risk exclusion in the EU trial record

> “Participants who are at higher risk of bleeding including participants with known bleeding diathesis, or who have current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.4-10"></a>

###### Central laboratory HPV confirmation in the initial trial-in-progress abstract

> “Eligible patients must have histologically confirmed R/M HNSCC with primary lesions in the oral cavity, larynx, or hypopharynx, or OPSCC, excluding HPV-positive OPSCC confirmed by central laboratory testing.”
> “Additional criteria include no prior systemic therapy for R/M disease, PD-L1 positive tumors (CPS ≥1), measurable disease per RECIST v1.1 assessed by BICR, and ECOG performance status of 0 or 1.”

Source: [Ferrarotto et al. (2025a)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.TPS6113)

<a id="topic-3.1.1.4-11"></a>

###### Central laboratory HPV confirmation in the updated trial-in-progress abstract

> “Eligible patients must have histologically confirmed R/M HNSCC with primary lesions in the oral cavity, larynx, or hypopharynx, or HPV-negative OPSCC confirmed by central laboratory testing.”
> “Additional eligibility criteria include no prior systemic therapy for R/M disease, PD-L1-positive tumor (CPS ≥1), measurable disease per RECIST v1.1, and ECOG performance status 0 or 1.”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

<a id="topic-3.1.1.4-12"></a>

###### Key eligibility criteria in the updated trial-in-progress poster

> “Eligible primary tumor locations: oral cavity, hypopharynx, larynx, or oropharynx (HPV negative if OPSCC)”
> “No prior systemic therapy for R/M disease, and completed systemic therapy >6 months prior if part of multimodal treatment for locoregionally advanced disease”
> “Prior therapy with an anti-EGFR antibody (except radiosensitizing and multimodal treatment for locoregionally advanced disease)”
> “Prior neoadjuvant and/or adjuvant immune checkpoint inhibitor therapy completed ≤6 months prior to study treatment initiation”
> “Patients at higher risk of bleeding (including known bleeding diathesis), with current active major bleeding, or major bleeding episode ≤4 weeks prior to enrollment”
> “1L R/M HNSCC excluding HPV-positive OPSCC”

Source: [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf)

<a id="topic-3.1.1.4-13"></a>

###### Population description in the first-enrollment press release

> “FORTIFI-HN01 is a global, randomized, double-blinded, placebo-controlled, pivotal Phase 2/3 trial that aims to enroll approximately 650 R/M HNSCC patients, excluding patients with human papillomavirus (HPV)-positive with oropharyngeal squamous cell carcinoma.”
> “Patients enrolled in the trial must have a PD-L1 CPS greater than or equal to one, and not have received systemic therapy in the R/M setting.”

Source: [Bicara Therapeutics FORTIFI-HN01 first enrollment announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-first-patients-enrolled-fortifi)

<a id="topic-3.1.1.4-14"></a>

###### HPV testing by primary site in the annual report

> “An estimated 80% of cases of R/M HNSCC are HPV-negative, with testing for HPV status typically only being conducted in tumors originating from the oropharynx.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="heading-3.1.1.5"></a>

##### 3.1.1.5 Treatment

<a id="topic-3.1.1.5-1"></a>

###### Treatment arms in the ClinicalTrials.gov record

| Arm | Quoted regimen |
| --- | --- |
| Phase 2 Arm A | “ficerafusp alfa 1500 mg QW + pembrolizumab 200 mg every 3 weeks (Q3W)” |
| Phase 2 Arm B | “ficerafusp alfa 750 mg QW + pembrolizumab 200 mg Q3W” |
| Phase 2 Arm C and Phase 3 Arm C (placebo comparator) | “placebo QW + pembrolizumab 200 mg Q3W” |
| Phase 3 OBD Arm | “ficerafusp alfa OBD + pembrolizumab 200 mg Q3W” |

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.5-2"></a>

###### Route, schedule, and duration in the updated trial-in-progress abstract

> “Patients receive pembrolizumab (200 mg IV every 3 weeks for up to 35 cycles) and either ficerafusp alfa or placebo IV QW until disease progression or unacceptable toxicity.”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

<a id="topic-3.1.1.5-3"></a>

###### Selected phase 3 dose and phase 2 crossover in the updated trial-in-progress poster

> “The Phase 3 portion is now enrolling with the optimal biological dose of ficerafusp alfa 1500 mg weekly in combination with pembrolizumab”
> “Following the decision on the optimal biologic dose (Phase 2), patients randomized to the 750 mg arm crossed over to the 1500 mg arm.”
> “This study was funded by Bicara Therapeutics Inc. with access to pembrolizumab in collaboration with Merck Sharp & Dohme LLC”

Source: [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf)

<a id="heading-3.1.1.6"></a>

##### 3.1.1.6 Study Outcomes

<a id="heading-3.1.1.6.1"></a>

###### 3.1.1.6.1 Rationale for Using RECIST v1.1 Objective Response Rate and Overall Survival as the Primary Endpoints

<a id="topic-3.1.1.6.1-1"></a>

###### Primary endpoints in the ClinicalTrials.gov record

| Primary endpoint | Quoted measure | Quoted definition | Quoted time frame |
| --- | --- | --- | --- |
| Phase 2 safety | “Phase 2 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.” | “To assess safety and tolerability of ficerafusp alfa with pembrolizumab.” | “Up to 30 days post end of treatment for TEAEs (90 days for SAEs).” |
| Phase 2 response | “Phase 2 - Objective Response Rate (ORR) per RECIST 1.1 by blinded independent central review (BICR)” | “ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.” | “Approximately 1 year.” |
| Phase 3 response | “Phase 3 - Objective Response Rate (ORR) per RECIST 1.1 by BICR.” | “ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.” | “Approximately 2 years.” |
| Phase 3 survival | “Phase 3 - Overall Survival (OS)” | “OS: Defined as the time from the randomization to death due to any cause.” | “Approximately 3 years.” |

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.6.1-2"></a>

###### Primary endpoints in the EU trial record

> “Phase 2 (Dose Selection) - ORR is defined as the proportion of participants in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.”
> “Phase 3 - OS: Defined as the time from the randomization to death due to any cause.”
> “Phase 3 - ORR: Defined as the proportion of the partcipants in the FAS who have confirmed CR or PR by BICR per RECIST 1.1. (Subset of FAS).”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.6.1-3"></a>

###### Secondary endpoints in the ClinicalTrials.gov record

> “Phase 2 - Duration of Response (DOR) per RECIST 1.1 by BICR.”
> “Phase 3 - Incidence and severity of TEAEs, treatment-treatment emergent SAEs TEAEs leading to dose interruption, dose reduction, or permanent discontinuation.”
> “Phase 3 - Progression-free survival (PFS) per RECIST 1.1 by BICR.”
> “ORR: Defined as confirmed CR + PR per RECIST 1.1 by BICR. (FAS).”
> “Phase 3 - Duration of Response (DOR) per RECIST 1.1 by BICR.”
> “Phase 3 - Clinical Benefit Rate (CBR) per RECIST 1.1 by BICR.”
> “Phase 3 - ORR, per RECIST 1.1 by investigator's assessment.”
> “Phase 3 - DOR, per RECIST 1.1 by investigator's assessment.”
> “Phase 3 - PFS, per RECIST 1.1 by investigator's assessment.”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.6.1-4"></a>

###### Patient-reported outcome endpoints in the ClinicalTrials.gov record

> “TTD is defined as the time from Baseline to the first onset of a ≥10-point negative change (decrease) from Baseline in QoL using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30 Item 30) score.”
> “Phase 3 - Time to deterioration (TTD) in pain measured by the EORTC HN 35 (items 31-34) pain domain.”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.6.1-5"></a>

###### Endpoint roles and tumor assessment schedule in the updated trial-in-progress abstract

> “The primary endpoints are objective response rate (ORR) per RECIST v1.1 (blind independent committee review) and overall survival.”
> “Tumor imaging occurs every 6 weeks during the first year and every 9 weeks thereafter.”
> “Secondary endpoints include safety, duration of response, progression free survival, clinical benefit rate, and patient-reported outcomes.”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

<a id="topic-3.1.1.6.1-6"></a>

###### Endpoint roles in the updated trial-in-progress poster

> “Phase 2: Safety and efficacy of the two doses to support selection of optimal biological dose”
> “Phase 3: ORR (interim analysis) and OS (final analysis)”
> “Exploratory endpoint”
> “Biomarker evaluation”

Source: [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf)

<a id="topic-3.1.1.6.1-7"></a>

###### Regulatory basis for the response and survival endpoints in the annual report

> “As a result of our discussions with the FDA, we believe that ficerafusp alfa has a path to accelerated approval using an ORR-based interim endpoint with confirmatory approval based on an OS endpoint.”
> “We believe the trial can support an accelerated approval on the basis of overall response rate, or ORR, six-month durability, and qualitative OS.”
> “Product candidates studied for their safety and effectiveness in treating serious conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-3.1.1.6.1-8"></a>

###### Regulatory basis in the first-enrollment press release

> “The primary endpoints are overall response rate based on RECIST v1.1 and overall survival, with results potentially supporting filings for both accelerated approval and full approval. Secondary endpoints include progression free survival and duration of response.”

Source: [Bicara Therapeutics FORTIFI-HN01 first enrollment announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-first-patients-enrolled-fortifi)

<a id="topic-3.1.1.6.1-9"></a>

###### FDA endpoint guidance on objective response rate and overall survival

> “While durable ORR has been used as a traditional approval endpoint in some circumstances, ORR has also been the most commonly used surrogate endpoint in support of accelerated approval.”
> “Tumor response is widely accepted by oncologists in guiding cancer treatments.”
> “Survival is considered the most reliable cancer endpoint, and when studies can be conducted to adequately assess survival, it is usually the preferred endpoint.”
> “Overall survival should be evaluated in randomized controlled studies.”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="topic-3.1.1.6.1-10"></a>

###### FDA draft guidance on one randomized trial for accelerated approval and verification of benefit

> “Alternatively, sponsors could design a single randomized controlled trial to support accelerated approval, that is also powered for the longer-term clinical endpoint with follow-up in the same trial to verify clinical benefit (i.e., “one-trial” approach).”

Source: [FDA (2023)](https://www.fda.gov/media/166431/download)

<a id="heading-3.1.1.7"></a>

##### 3.1.1.7 Statistical Analysis Description

<a id="heading-3.1.1.7.1"></a>

###### 3.1.1.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.1.7.1-1"></a>

###### Planned enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 650”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.7.1-2"></a>

###### Planned enrollment and power in the annual report

> “The total trial will enroll approximately 650 patients, which we believe is sufficiently powered to achieve results that may lead to regulatory approval.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-3.1.1.7.1-3"></a>

###### Planned enrollment in the updated trial-in-progress abstract

> “The trial is actively recruiting, with planned enrollment of ~650 subjects.”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

<a id="topic-3.1.1.7.1-4"></a>

###### Planned enrollment in the updated trial-in-progress poster

> “It is planned that about 650 people will take part in this trial.”
> “Two out of every three participants also receive ficerafusp alfa, and one out of every three participants also receive a placebo”

Source: [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf)

<a id="heading-3.1.1.7.2"></a>

###### 3.1.1.7.2 Description of Analysis Sets

<a id="topic-3.1.1.7.2-1"></a>

###### Response analysis sets in the ClinicalTrials.gov record

> “ORR is defined as the proportion of subjects in the DDS who have a confirmed CR or PR per RECIST 1.1. by BICR.”
> “ORR: Defined as confirmed CR + PR per RECIST 1.1 by BICR. (FAS).”

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990)

<a id="topic-3.1.1.7.2-2"></a>

###### Response analysis set in the EU trial record

> “Phase 3 - ORR: Defined as the proportion of the partcipants in the FAS who have confirmed CR or PR by BICR per RECIST 1.1. (Subset of FAS).”

Source: [EU CTIS 2024-519654-37-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2024-519654-37-00)

<a id="topic-3.1.1.7.2-3"></a>

###### Phase 2 participants contributing to the primary analyses in the annual report

> “Importantly, our Phase 2/3 FORTIFI-HN01 trial design enables the patients enrolled in the 1500mg QW treatment arm during dose selection to contribute to the primary analyses of the FORTIFI-HN01 pivotal trial, while those enrolled in the 750mg QW treatment arm will not (but will have the option to roll over to the 1500mg QW dose).”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-3.1.1.7.2-4"></a>

###### Interim and final analyses in the trial-in-progress materials

> “An interim analysis evaluating ORR is planned.”

Source: [Ferrarotto et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.TPS6129)

> “Phase 3: Dual primary endpoints”
> “ORR (interim analysis)”
> “OS (final analysis)”

Source: [Ferrarotto et al. (2025b)](https://www.bicara.com/wp-content/uploads/2025/06/FINAL_Bicara_ASCO_TiP_Poster-1.pdf)

<a id="topic-3.1.1.7.2-5"></a>

###### Interim analysis timing in the third-quarter results press release

> “Achieved substantial enrollment in the FORTIFI-HN01 pivotal trial in first-line (1L) recurrent or metastatic (R/M) human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC), to enable topline results from an interim analysis in mid-2027.”

Source: [Bicara Therapeutics third quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2026-financial-results)

<a id="heading-3.1.1.8"></a>

##### 3.1.1.8 Results

<a id="heading-3.1.1.8.1"></a>

###### 3.1.1.8.1 Participant Disposition

<a id="topic-3.1.1.8.1-1"></a>

###### First enrollment in the press release

> “today announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab in 1L (first line) recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)”

Source: [Bicara Therapeutics FORTIFI-HN01 first enrollment announcement (2025)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-first-patients-enrolled-fortifi)

<a id="topic-3.1.1.8.1-2"></a>

###### Completion of phase 2 and transition to phase 3 in the annual report

> “In January 2026, we announced that 1500mg QW of ficerafusp alfa was selected as the optimal dose to bring forward in the Phase 3 portion of the FORTIFI-HN01 trial. In February 2026, the transition to the Phase 3 portion of the FORTIFI-HN01 trial was completed.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-3.1.1.8.1-3"></a>

###### Phase 2 arm disposition in the updated trial-in-progress poster

> “750 mg arm discontinued”
> “The Phase 2 portion is complete”
> “Following the decision on the optimal biologic dose (Phase 2), patients randomized to the 750 mg arm crossed over to the 1500 mg arm.”

Source: [Ferrarotto et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Ferrarotto_2026_ASCO_Poster_FORTIFI-HN01-TiP_FINAL-APPROVED.pdf)

<a id="topic-3.1.1.8.1-4"></a>

###### Enrollment status in the quarterly report

> “In November 2026, we announced that FORTIFI-HN01 reached substantial enrollment to enable an interim analysis in mid-2027 to support a potential approval and U.S. launch in 2028.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="heading-3.1.1.8.2"></a>

###### 3.1.1.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.1.8.3"></a>

###### 3.1.1.8.3 Efficacy Results

<a id="topic-3.1.1.8.3-1"></a>

###### Phase 2 dose selection outcome in the press release

> “Selected 1500 mg QW of ficerafusp alfa in combination with pembrolizumab as the optimal dose for Phase 3 FORTIFI-HN01 pivotal study, earlier than anticipated”
> “Bicara has aligned with the U.S. Food and Drug Administration (FDA) on a clear path to implement, by the end of the first quarter, the optimal dose for Phase 3 of FORTIFI-HN01, a global, randomized, double-blind, placebo-controlled, pivotal trial of ficerafusp alfa in combination with pembrolizumab in first-line (1L) human papillomavirus (HPV)-negative recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).”

Source: [Bicara Therapeutics phase 3 dose and 2026 outlook announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-announces-phase-3-optimal-dose-and-provides)

<a id="topic-3.1.1.8.3-2"></a>

###### Data informing dose selection in the annual report

> “The dose determination was informed by the open-label data sets from our Phase 1/1b trial, as well as data from the treatment arms of the Phase 2 portion of the FORTIFI-HN01 trial.”
> “These data supported the selection of 1500mg QW of ficerafusp alfa as the optimal dose to advance into the Phase 3 portion of our FORTIFI-HN01 pivotal trial.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-3.1.1.8.3-3"></a>

###### Biomarker basis for dose selection in the full-year results press release

> “Biomarker analyses demonstrated that the 1500mg dose achieved greater TGF-β inhibition, stronger immune activation, and deeper clinical responses, supporting higher dose selection and further derisking the ORR interim analysis for the FORTIFI-HN01 pivotal study.”

Source: [Bicara Therapeutics fourth quarter and full year 2025 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-fourth-quarter-and-full-year-2025)

<a id="heading-3.1.1.8.4"></a>

###### 3.1.1.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.1.8.5"></a>

###### 3.1.1.8.5 Safety Results

No evidence found.

<a id="heading-3.1.1.9"></a>

##### 3.1.1.9 Study Limitations

<a id="topic-3.1.1.9-1"></a>

###### Summary

FORTIFI-HN01 has reported no efficacy, safety, or baseline results; the phase 3 dose selection rests on company statements that it was informed by the open-label phase 1/1b data sets and by data from the phase 2 treatment arms. Accelerated approval would rest on an interim ORR analysis, with clinical benefit verified by OS in the same trial, the design FDA draft guidance calls the “one-trial” approach; FDA draft guidance states that preserving trial integrity is critical to that approach, and Bicara states that “interim and preliminary data may not be predictive of final results” and that confirmatory studies may not show clinical benefit. The control arm is placebo plus pembrolizumab 200 mg every 3 weeks, and participants treated at 1500 mg weekly in phase 2 contribute to the primary analyses while those treated at 750 mg weekly do not.

Source: [ClinicalTrials.gov NCT06788990](https://clinicaltrials.gov/study/NCT06788990); [FDA (2023)](https://www.fda.gov/media/166431/download); [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm); [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-3.1.1.9-2"></a>

###### Verification of clinical benefit after accelerated approval in the annual report

> “Moreover, even if we received accelerated approval, any post-approval studies required to confirm and verify clinical benefit may not show such benefit, which could lead to withdrawal of any approvals we have obtained.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-3.1.1.9-3"></a>

###### Interim data in the quarterly report

> “As a result, interim and preliminary data may not be predictive of final results and should be viewed with caution until the final data are available.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-3.1.1.9-4"></a>

###### Potential bias in a single-trial accelerated approval design in FDA draft guidance

> “Preserving the integrity of the trial is critical in assessing the feasibility and appropriateness of the “one-trial” approach because the evaluation of the data and subsequent regulatory action on an accelerated approval application may inadvertently introduce bias.”

Source: [FDA (2023)](https://www.fda.gov/media/166431/download)

<a id="heading-3.1.2"></a>

#### 3.1.2 BCA101X1101

<a id="heading-3.1.2.1"></a>

##### 3.1.2.1 Objective

<a id="topic-3.1.2.1-1"></a>

###### Registry title and purpose

> “First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-Driven Advanced Solid Tumors”
> “The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ.”

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.1-2"></a>

###### Dose escalation: safety, tolerability, and maximum tolerated dose

> “The primary objective of this study was to assess safety and tolerability and to determine the MTD of ficerafusp alfa as monotherapy and in combination with pembrolizumab.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.1-3"></a>

###### First-line HNSCC expansion cohort at 1500 mg weekly: safety and antitumor activity

> “Does ficerafusp alfa show acceptable safety and antitumor activity when combined with pembrolizumab for first-line treatment of PD-L1–positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)?”
> “The primary objective was to characterize safety and tolerability in the safety set (patients who received ≥1 dose of study treatment), including TEAEs and TRAEs (defined as any TEAE deemed related to ficerafusp alfa or pembrolizumab).”
> “The secondary objective for the HNSCC dose-expansion cohort was to explore the antitumor activity of ficerafusp alfa in the efficacy-evaluable set (EES; treated patients with ≥1 postbaseline scan).”
> “Exploratory objectives included evaluation of pharmacodynamic markers.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.1-4"></a>

###### Integrated analysis of the three first-line dose cohorts

> “Herein we present an integrated analysis of all three dose cohorts with extended follow-up, highlighting TGF-β inhibition, depth of response, long-term survival outcomes, and sustained disease control”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

> “This is the first report of long-term efficacy follow-up across two cohorts of ficerafusp alfa.”

Source: [Wong et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6040)

<a id="heading-3.1.2.2"></a>

##### 3.1.2.2 Location and Study Date

<a id="topic-3.1.2.2-1"></a>

###### Registry study dates

| Study characteristic | Quoted record |
| --- | --- |
| Study start (actual) | “2020-06-01” |
| Primary completion (estimated) | “2027-10-31” |
| Study completion (estimated) | “2028-03-30” |

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.2-2"></a>

###### Registry study sites

| Country | Quoted site |
| --- | --- |
| United States | “Moores Cancer Center UC San Diego Health” |
| United States | “Keck School of Medicine of USC” |
| United States | “University of California, Davis Comprehensive Cancer Center” |
| United States | “H. Lee Moffitt Cancer Center and Research Institute, Inc” |
| United States | “Dana Farber/Partners Cancer Care Inc” |
| United States | “Memorial Sloan Kettering” |
| United States | “Columbia University Herbert Irving Comprehensive Cancer Center” |
| United States | “Levine Cancer Institute” |
| United States | “Cleveland Clinic” |
| United States | “UPMC Hillman Cancer Center” |
| United States | “Rhode Island Hospital” |
| United States | “Medical University of South Carolina, Hollings Cancer Center” |
| United States | “Vanderbilt University Medical Center” |
| United States | “MD Anderson Cancer Center” |
| Australia | “Chris O'Brien Lifehouse” |
| Australia | “Calvary Mater Newcastle” |
| Australia | “Austin Hospital” |
| Australia | “Peter MacCallum Cancer Centre” |
| Canada | “Princess Margaret Cancer Centre” |
| Canada | “Centre hospitalier de l'Université de Montréal (CHUM)” |

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.2-3"></a>

###### Dose escalation enrollment period and data cutoff

> “Between June 25, 2020, and June 9, 2022, 61 patients were enrolled”
> “The data cutoff for the data reported was April 17, 2024.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.2-4"></a>

###### First-line 1500 mg weekly cohort enrollment period, data snapshot, and geography

> “Between February 2022 and April 2023, 51 patients were screened”
> “As of the data snapshot (March 20, 2025)”
> “limited geographic scope (the United States and Canada)”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.2-5"></a>

###### First-line 750 mg weekly cohort data snapshot

> “Data snapshot: July 9, 2025.”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.2-6"></a>

###### First-line 2000 mg every 2 weeks cohort data snapshot

> “Data snapshot: December 16, 2025.”

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="topic-3.1.2.2-7"></a>

###### Integrated analyses of the first-line cohorts: data cutoffs

> “As of December 16, 2025, 61 HPV-neg pts were treated in two cohorts (750 mg, n=31; 1500 mg, n=30); 58 pts were efficacy evaluable.”

Source: [Wong et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6040)

> “As of March 31, 2026, 91 patients received the study drug (safety analysis [SA] set) and 85 were evaluable for efficacy (efficacy evaluable [EE] set)”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="heading-3.1.2.3"></a>

##### 3.1.2.3 Study Design

<a id="topic-3.1.2.3-1"></a>

###### Registry design: nonrandomized, open-label, parallel assignment

| Study characteristic | Quoted record |
| --- | --- |
| Protocol number | “BCA101X1101” |
| Merck study identifier | “KEYNOTE-E28” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.3-2"></a>

###### Registry design: dose escalation (Part A) followed by expansion cohorts (Part B)

> “This is a Phase 1/1b, open-label study, which consists of dose escalation parts (Part A) followed by expansion cohorts (Part B) for both single agent BCA101 and combination BCA101 plus pembrolizumab.”
> “Dose escalation (Part A) of combination BCA101 and pembrolizumab consists of subjects with either Squamous Cell Carcinoma of the Head and Neck (HNSCC) or Squamous Cell Carcinoma of the Anal Canal (SCCAC) whose tumors are refractory to standard of care or for whom no standard of care is available.”
> “Once the maximum tolerated dose (MTD) / recommended dose (RD) of single agent BCA101 is determined, the study will continue with expansion cohorts (Part B) with select tumor types.”
> “Planned expansion cohorts for the combination of BCA101 and pembrolizumab include: 1) HNSCC and 2) SCCAC.”

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.3-3"></a>

###### Dose escalation: parallel 3 + 3 design with backfilling

> “Dose escalation in this first-in-human phase I clinical trial (BCA101X1101) followed a parallel 3 + 3 design for both ficerafusp alfa monotherapy and ficerafusp alfa in combination with pembrolizumab”
> “Backfilling of up to six additional patients was allowed once acceptable safety had been demonstrated for the respective dose level.”
> “Once the first two dose levels of ficerafusp alfa monotherapy were determined to be safe, enrollment in the combination started.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.3-4"></a>

###### First-line HNSCC dose-expansion cohort reported separately from escalation

> “This open-label, multicenter, prospective, nonrandomized, first-in-human, phase I/Ib study (ClinicalTrials.gov identifier: NCT04429542) evaluated ficerafusp alfa as monotherapy and in combination with pembrolizumab for patients with advanced EGFR-driven solid tumors.”
> “After determination of the recommended dose, expansion cohorts were enrolled”
> “dose-escalation patients were not included in the dose-expansion cohort”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.3-5"></a>

###### Three first-line HPV-negative dose-expansion cohorts under a Simon two-stage design

> “Part B: Dose expansion in 1L R/M HPV-negative HNSCC”
> “(Simon 2-stage design)”
> “Preliminary evaluations of the 750 mg weekly (QW), 1500 mg QW, and 2000 mg every 2 weeks (Q2W) cohorts successfully established early clinical activity and tolerability of the bifunctional mechanism”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.3-6"></a>

###### Rationale for the 750 mg weekly and 2000 mg every 2 weeks cohorts

> “This is one of two doses being evaluated for optimal biologic dose in the ongoing phase 2/3 FORTIFI-HN01 study”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

> “Ficerafusp alfa’s half-life of ~ 8 days supports the rationale to explore less frequent dosing schedules”

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="heading-3.1.2.4"></a>

##### 3.1.2.4 Eligibility Criteria

<a id="topic-3.1.2.4-1"></a>

###### Registry criteria for the first-line HNSCC combination cohort (expansion cohort 2)

> “Expansion Cohort 2: Head and Neck Squamous Cell Carcinoma (HNSCC), metastatic or unresectable, recurrent with a Combined Positive Score (CPS) equal to or greater than 1, as determined by an CLIA-approved laboratory test.”
> “Primary tumor locations of oropharynx, oral cavity, hypopharynx, or larynx.”
> “Participants may not have a primary tumor site of nasopharynx (any histology).”
> “Patients must have no prior systemic therapy administered in the recurrent or metastatic setting (with the exception of systemic therapy completed >6 months prior if given as part of multimodal treatment for locally advanced disease) or prior history of immune checkpoint inhibitors with the exception of neoadjuvant therapy (>6 months prior to study drug initiation).”
> “No prior history of anti-EGFR antibodies (with the exception of radiosensitizing agents and multimodal treatment for locally advanced disease).”
> “Patients must provide tissue for PD-L1 biomarker analysis from a core or excisional biopsy (fine needle aspirate is not sufficient): A newly obtained biopsy (within 90 days prior to start of study treatment) is preferred but an archival sample is acceptable.”
> “Patients must have results from testing of human papillomavirus (HPV) status for oropharyngeal cancer”

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.4-2"></a>

###### Registry criteria for the HNSCC cohort with CPS less than 1 (expansion cohort 6)

> “Expansion Cohort 6: Head and Neck Squamous Cell Carcinoma (HNSCC), metastatic or unresectable, recurrent with a Combined Positive Score (CPS) less than 1, as determined by PD-L1 IHC 22C3 pharmDx.”

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.4-3"></a>

###### Registry criteria common to all cohorts

> “Patient must have a performance status of ≤1 on the Eastern Cooperative Oncology Group Performance Scale.”
> “Patient must have measurable disease amendable to biopsy and be willing to undergo both a pre-treatment and on-treatment biopsy”
> “Prior treatment with any anti-TGFβ therapy.”
> “Prior history of Grade ≥ 2 intolerance or hypersensitivity reaction to cetuximab or other anti-EGFR therapy or other murine proteins or prior discontinuation of therapy in the setting of toxicity related to treatment.”

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.4-4"></a>

###### First-line 1500 mg weekly cohort: published eligibility, PD-L1 assay, and HPV determination

> “Eligible study patients were age 18 years and older and had pathologically confirmed, unresectable R/M HNSCC (including primary tumors in the oral cavity, oropharynx, hypopharynx, and larynx)”
> “Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 or 1; and adequate hepatic, renal, and hematologic function.”
> “Patients with prior systemic therapy for R/M disease were ineligible.”
> “Patients with prior platinum chemotherapy or anti-EGFR or anti–PD-1 treatment for locoregionally advanced HNSCC completed >6 months before enrollment were eligible.”
> “All patients were required to have tumor PD-L1 CPS ≥1 (assessed locally in archival or fresh samples using the 22C3 immunohistochemistry or other validated assay), and for oropharyngeal primary tumors, p16 immunohistochemistry or HPV molecular test result.”
> “Twelve oropharyngeal tumors were classified as HPV-positive, whereas all oral cavity, hypopharynx, and larynx tumors were considered HPV-negative per current clinical standard.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.4-5"></a>

###### Integrated first-line HPV-negative analysis: key inclusion criteria

> “Primary tumor in oral cavity, oropharynx, larynx, or hypopharynx”
> “PD-L1 CPS was assessed locally in archival or fresh samples using the 22C3 immunohistochemistry or other validated assay.”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

> “Two dose-expansion cohorts of an ongoing phase 1/1b study (NCT04429542) enrolled adults with 1L R/M HNSCC with PD-L1 CPS ≥1.”

Source: [Wong et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6040)

<a id="topic-3.1.2.4-6"></a>

###### First-line 750 mg weekly and 2000 mg every 2 weeks cohorts: HPV-negative population

> “1L R/M HNSCC, HPV-negative”
> “Oral cavity, oropharynx, larynx, and hypopharynx”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

> “Oral cavity, oropharynx, larynx, or hypopharynx”

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="topic-3.1.2.4-7"></a>

###### Dose escalation combination cohort eligibility

> “For the dose-escalation cohort receiving ficerafusp alfa in combination with pembrolizumab, tumor types included recurrent unresectable or metastatic (R/M) HNSCC and SCAC.”
> “Patients were eligible regardless of the number of previous lines of systemic therapy.”
> “EGFR tumor tissue expression testing was not required for participation.”
> “Patients were ineligible if they had a history of gastrointestinal bleeding 4 weeks prior to enrollment, a history of clinically significant cardiac valvular disease, previous treatment with anti–TGF-β therapy, or a prior history of grade ≥2 intolerance or hypersensitivity reaction to cetuximab or other anti-EGFR therapy”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="heading-3.1.2.5"></a>

##### 3.1.2.5 Treatment

<a id="topic-3.1.2.5-1"></a>

###### Registry arms

| Arm | Quoted arm description |
| --- | --- |
| BCA101 monotherapy | “Route: IV Infusion Frequency: QW Current Dose: 1500mg” |
| BCA101 plus pembrolizumab | “Route: IV Infusion Frequency: Q3W Dose: 200mg” |

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.5-2"></a>

###### Dose escalation: dose range, starting doses, and infusion

> “At escalating doses in a parallel 3 + 3 design, patients with EGFR-driven advanced solid tumors received weekly intravenous ficerafusp alfa as monotherapy (64–1,500 mg) or in combination (240–1,500 mg) with pembrolizumab (200 mg i.v. every 3 weeks).”
> “The starting dosage of ficerafusp alfa in monotherapy for patients enrolled in the study was set at 64 mg i.v. administered continuously once weekly.”
> “The selected starting dosage followed the International Council for Harmonization S9 guidelines.”
> “Ficerafusp alfa was administered as an infusion over 120 minutes.”
> “The starting dosage of ficerafusp alfa in combination with pembrolizumab was 240 mg i.v. once weekly.”
> “Pembrolizumab 200 mg i.v. was administered after ficerafusp alfa as a 30-minute infusion every 3 weeks (cycle length, 21 days).”
> “64, 240, 500, 750, 800, 1,000, 1,250, and 1,500 mg”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.5-3"></a>

###### First-line 1500 mg weekly regimen and dose modification rules

> “Eligible patients received pembrolizumab 200 mg intravenously (IV) on day 1 and ficerafusp alfa 1,500 mg IV on days 1, 8, and 15 in 21-day cycles until disease progression, death, unacceptable toxicity, loss to follow-up, or withdrawal of consent.”
> “Treatment beyond progression was permitted at the discretion of the treating investigator if the patient was deriving clinical benefit.”
> “Pembrolizumab was interrupted or discontinued (dose reduction not permitted) for grade ≥3 immune-related adverse events (AEs) per investigator assessment.”
> “The infusion rate of ficerafusp alfa was reduced by 50% for grade 1/2 or nonserious infusion-related reactions (IRRs); ficerafusp alfa was permanently discontinued for grade ≥3 or serious IRRs.”
> “Grade ≥3 AEs resulted in interruption, dose modification (ficerafusp alfa only), or permanent discontinuation according to study drug attribution.”
> “Topical steroids and/or antibiotics were recommended as prophylaxis or treatment for acneiform dermatitis.”
> “Patients who discontinued one study drug for any reason other than disease progression could continue the other per investigator discretion.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.5-4"></a>

###### First-line 750 mg weekly regimen

> “Patients received ficerafusp alfa 750 or 1500 mg IV on D1, 8, and 15 plus pembrolizumab (pembro) 200 mg IV Q3W.”

Source: [Wong et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6040)

> “Ficerafusp alfa 750 mg QW + Pembrolizumab 200 mg Q3W”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.5-5"></a>

###### First-line 2000 mg every 2 weeks regimen

> “Ficerafusp alfa 2000 mg Q2W + Pembrolizumab 400 mg Q6W”

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="topic-3.1.2.5-6"></a>

###### Escalation and expansion regimens in the integrated analysis

> “Ficerafusp alfa 240-1500 mg QW IV”
> “Pembrolizumab 200 mg Q3W IV”
> “MTD not reached”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="heading-3.1.2.6"></a>

##### 3.1.2.6 Study Outcomes

<a id="heading-3.1.2.6.1"></a>

###### 3.1.2.6.1 Rationale for Using Dose-limiting Toxicities and Adverse Events as the Primary Endpoints

<a id="topic-3.1.2.6.1-1"></a>

###### Registry primary outcomes

| Outcome | Quoted measure | Quoted time frame |
| --- | --- | --- |
| Safety | “Safety of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs” | “24 months” |
| Tolerability | “Tolerability of BCA101 alone and BCA101 in combination with pembrolizumab: Incidence and severity of AEs and SAEs” | “24 months” |
| Dose-limiting toxicities | “Incidence of DLTs during the first cycle of treatment with BCA101 monotherapy or the combination of BCA101 and pembrolizumab.” | “21 days” |

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.6.1-2"></a>

###### Registry secondary outcomes and response criteria

| Outcome | Quoted description |
| --- | --- |
| Objective response rate | “Determine objective response rate in each part of the study, per RECIST v1.1 and iRECIST” |
| Clinical benefit rate | “Determine clinical benefit rate in each part of the study, per RECIST v1.1 and iRECIST” |
| Progression-free survival | “Determine PFS in each part of the study, per RECIST v1.1 and iRECIST” |
| Duration of response | “Determine duration of response in each part of the study, per RECIST v1.1 and iRECIST” |
| Overall survival | “Determine survival rates in each part of the study.” |
| Immunogenicity | “Incidence and titer of anti-drug-antibodies” |

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.6.1-3"></a>

###### Dose escalation: dose-limiting toxicity as the primary endpoint

> “The primary endpoint was the incidence of dose-limiting toxicities (DLT).”
> “DLTs were defined as an adverse event or abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications occurring within the first 21 days of treatment with ficerafusp alfa”
> “Secondary objectives included the characterization of the pharmacokinetic (PK) and immunogenicity profile of ficerafusp alfa and preliminary antitumor activity of ficerafusp alfa as monotherapy and in combination with pembrolizumab as assessed by the investigator by RECIST version 1.1”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.6.1-4"></a>

###### First-line 1500 mg weekly cohort: safety as the primary endpoint and efficacy endpoint definitions

> “The primary end point was safety.”
> “Secondary end points included objective response rate (ORR), progression-free survival (PFS), duration of response (DOR), and overall survival (OS).”
> “End points included ORR; clinical benefit rate (CBR; best response of complete response [CR], partial response [PR], or stable disease [SD] for ≥5 weeks); DOR (time from first assessment of CR or PR to first documentation of progressive disease [PD] or death, whichever occurred earlier); and progression-free survival (PFS) and OS (time from study enrollment to the first occurrence of progression or death [whichever occurred earlier] or death, respectively).”
> “Imaging assessments were performed at baseline, every 6 weeks during treatment until cycle 13, then every 9 weeks thereafter.”
> “AEs were classified using preferred terms according to the Medical Dictionary for Regulatory Activities, and were graded using National Cancer Institute Common Terminology Criteria for Adverse Events version 5.”
> “investigator-assessed according to RECIST v1.1”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.6.1-5"></a>

###### Safety findings informing subsequent trials

> “Safety findings from this phase I/Ib study have informed the design of subsequent studies of ficerafusp alfa and pembrolizumab, including mitigation strategies for AEs of special interest.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.6.1-6"></a>

###### Depth of response: definition

> “Deep response is defined as ≥80% tumor regression in target lesions vs baseline.”
> “Table shows investigator-assessed best overall response per RECIST 1.1.”

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

> “Deep response (≥80% tumor shrinkage)”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.6.1-7"></a>

###### Depth of response: rationale for exploratory analysis

> “Depth of response has been shown to correlate with prolonged progression free survival (PFS) and overall survival (OS) in several solid tumors. However, such data are limited in R/M HPV-negative HNSCC.”
> “In the pooled efficacy evaluable set from the three cohorts, we explored if the magnitude of tumor regression, comparing tumor regression ≥80% regression (defined as a deep response) vs. tumor regression 0 to <80%, is predictive of longer-term clinical outcomes (DOR, PFS, OS).”
> “This suggests that depth of response may represent a clinically meaningful surrogate for understanding long-term efficacy outcomes in HPV-negative HNSCC.”

Source: [Kaczmar et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6058)

<a id="topic-3.1.2.6.1-8"></a>

###### Objective response rate and depth of response as support for the pivotal interim analysis

> “the consistently high ORRs and depth of response validate the planned ORR-based interim analysis in the ongoing FORTIFI-HN01 trial”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="heading-3.1.2.7"></a>

##### 3.1.2.7 Statistical Analysis Description

<a id="heading-3.1.2.7.1"></a>

###### 3.1.2.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.2.7.1-1"></a>

###### Registry planned enrollment across all cohorts

| Study characteristic | Quoted record |
| --- | --- |
| Enrollment (estimated) | “473” |

Source: [ClinicalTrials.gov NCT04429542](https://clinicaltrials.gov/study/NCT04429542)

<a id="topic-3.1.2.7.1-2"></a>

###### Dose escalation: participants enrolled

> “Among 61 patients (monotherapy, n = 46; combination, n = 15)”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.7.1-3"></a>

###### First-line 1500 mg weekly cohort: Simon two-stage sample size and participants analyzed

> “A Simon 2-stage optimal design was used, in which the treatment regimen warrants further evaluation if >3 objective responses were observed among the first 18 eligible patients.”
> “The regimen was deemed promising if >10/39 patients in the EES had an objective response.”
> “The design yielded 90.1% power to rule out a 19% CBR and detect a 38% ORR (using a one-sided exact binomial test with a type I error rate of 9.7%).”
> “Between February 2022 and April 2023, 51 patients were screened (Fig 1), 42 patients received ≥1 dose of study drug, and 39 patients were evaluable for efficacy.”
> “In efficacy-evaluable patients with HPV-negative (n = 28) or HPV-positive (n = 11) tumors”
> “The median follow-up was 26.3 months (range, 23.9-29.4).”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.7.1-4"></a>

###### First-line 750 mg weekly cohort: participants analyzed

> “Dose-expansion cohort (n=31)”
> “Efficacy-evaluable population (n=30)”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.7.1-5"></a>

###### First-line 2000 mg every 2 weeks cohort: participants analyzed

> “Dose-expansion cohort (N=30)”
> “EE set (N=27)”

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="topic-3.1.2.7.1-6"></a>

###### Integrated first-line HPV-negative analyses: participants analyzed and follow-up

> “In the 750 mg QW, 1500 mg QW, and 2000 mg Q2W cohorts, respectively:”
> “Patient numbers in the SA/EE populations were 31/30, 30/28, and 30/27”
> “Median (95% CI) follow-up was 20 (20-22), 36 (36-43) and 24 (12-27) months”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

> “85 patients with HPV-negative disease were efficacy evaluable across three cohorts (n=30, n=28, and n=27 at 750mg, 1500mg, and 2000mg doses of ficerafusp alfa, respectively).”

Source: [Kaczmar et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6058)

<a id="heading-3.1.2.7.2"></a>

###### 3.1.2.7.2 Description of Analysis Sets

<a id="topic-3.1.2.7.2-1"></a>

###### Dose escalation analysis sets

> “Descriptive statistics were used to summarize all patient characteristics, treatment administration and compliance, efficacy endpoints, and safety parameters.”
> “The safety set included all patients who received at least one dose of study treatment, ficerafusp alfa or pembrolizumab.”
> “The dose-determining set included all patients in the safety set who enrolled during dose escalation and either experienced a DLT at any time during the DLT evaluation period (first 21 days) or had all required safety assessments without experiencing a DLT within the DLT evaluation period.”
> “The efficacy-evaluable set included all patients who received at least one dose of study treatment and had at least one post-baseline tumor assessment as defined in the protocol at or beyond the first post-baseline visit for tumor assessment.”
> “If a patient had progressive disease before the first post–baseline assessment visit, they were also included in the efficacy-evaluable set.”
> “The PK analysis set consisted of all patients who had at least one blood sample providing evaluable PK data.”
> “The duration of response analysis was performed using Kaplan–Meier methods.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.7.2-2"></a>

###### First-line 1500 mg weekly cohort analysis sets and HPV subgroups

> “safety set (patients who received ≥1 dose of study treatment)”
> “efficacy-evaluable set (EES; treated patients with ≥1 postbaseline scan)”
> “PFS and OS were estimated using the Kaplan-Meier method.”
> “Efficacy was analyzed in the EES (n = 39).”
> “Samples collected from patients who missed a previous dose of ficerafusp alfa were excluded from pharmacodynamic analyses.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.7.2-3"></a>

###### Integrated first-line analysis restricted to HPV-negative participants

> “The 1500 mg QW cohort also enrolled HPV-positive patients, who were not included in the current analysis.”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.7.2-4"></a>

###### Pooled efficacy-evaluable set for the depth of response analysis

> “Here we performed exploratory analyses to evaluate whether depth of response achieved with ficerafusp alfa and pembrolizumab is associated with prolonged duration of response (DOR), PFS and OS.”

Source: [Kaczmar et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6058)

<a id="heading-3.1.2.8"></a>

##### 3.1.2.8 Results

<a id="heading-3.1.2.8.1"></a>

###### 3.1.2.8.1 Participant Disposition

<a id="topic-3.1.2.8.1-1"></a>

###### Dose escalation: participants excluded from the efficacy-evaluable set

> “Of the 46 patients treated with ficerafusp alfa monotherapy, four patients did not have a post-baseline assessment and were excluded from the efficacy-evaluable population.”
> “Among the 15 patients treated with ficerafusp alfa in combination with pembrolizumab, 13 patients were RECIST 1.1 evaluable, and two patients discontinued treatment because of adverse events before the first post-baseline efficacy assessment”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.8.1-2"></a>

###### First-line 1500 mg weekly cohort: screening, treatment status, and follow-up

> “Between February 2022 and April 2023, 51 patients were screened (Fig 1), 42 patients received ≥1 dose of study drug, and 39 patients were evaluable for efficacy.”
> “As of the data snapshot (March 20, 2025), three patients (8%) remained on study treatment and 36 (92%) had discontinued, most often for PD (20 [51%]; Appendix Table A1); 12 (31%) remained in follow-up.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.1-3"></a>

###### First-line 1500 mg weekly cohort: reasons for treatment or study discontinuation

| Status or reason | Safety set (N = 42), No. (%) | Efficacy-evaluable set (n = 39), No. (%) |
| --- | --- | --- |
| Treatment ongoing | “3 (7)” | “3 (7)” |
| Treatment discontinuation | “39 (93)” | “36 (92)” |
| Treatment discontinuation: progression of disease | “21 (50)” | “20 (51)” |
| Treatment discontinuation: adverse event | “10 (24)” | “8 (21)” |
| Treatment discontinuation: patient withdrawal | “5 (12)” | “5 (13)” |
| Treatment discontinuation: investigator discretion | “3 (7)” | “3 (8)” |
| Study follow-up ongoing | “12 (29)” | “12 (31)” |
| Study follow-up discontinued | “30 (71)” | “27 (69)” |
| Study follow-up discontinued: death | “29 (69)” | “26 (67)” |
| Study follow-up discontinued: patient withdrawal | “1 (2)” | “1 (3)” |
| Study follow-up discontinued: lost to follow-up | “0” | “0” |

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.1-4"></a>

###### First-line 750 mg weekly cohort: participant not evaluable for efficacy

> “1 patient was not evaluable for efficacy due to early death unrelated to treatment.”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.8.1-5"></a>

###### First-line 1500 mg weekly cohort: participants on treatment at the most recent data cut

> “After a median follow-up of 36 months, median DOR in the 1500 mg QW cohort was of 21.7 months, with 10% of patients (n=3) remaining on active treatment.”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="heading-3.1.2.8.2"></a>

###### 3.1.2.8.2 Baseline Characteristics

<a id="topic-3.1.2.8.2-1"></a>

###### First-line HPV-negative dose cohorts at the March 2026 data cut

| Characteristic | 750 mg QW (N=31) | 1500 mg QW (N=30) | 2000 mg Q2W (N=30) |
| --- | --- | --- | --- |
| Age, median (min-max) | “64 (28-78)” | “63 (31-84)” | “63 (32-94)” |
| Male, n (%) | “20 (65)” | “19 (63)” | “20 (67)” |
| Female, n (%) | “11 (35)” | “11 (37)” | “10 (33)” |
| Oral cavity, n (%) | “19 (61)” | “14 (47)” | “19 (63)” |
| Oropharynx (HPV negative), n (%) | “4 (13)” | “8 (27)” | “6 (20)” |
| Hypopharynx, n (%) | “5 (16)” | “4 (13)” | “2 (7)” |
| Larynx, n (%) | “3 (10)” | “4 (13)” | “3 (10)” |
| CPS 1-19, n (%) | “12 (39)” | “15 (50)” | “15 (50)” |
| CPS ≥20, n (%) | “19 (61)” | “15 (50)” | “15 (50)” |
| Locoregional only, (%) | “16 (52)” | “9 (30)” | “19 (63)” |
| Distant metastatic only, (%) | “5 (16)” | “7 (23)” | “5 (17)” |
| Locoregional and distant metastatic, (%) | “10 (32)” | “14 (47)” | “6 (20)” |
| Target lesion diameter (mm) at baseline, median (min-max) | “41 (11-131)” | “49 (10-133)” | “33 (10-187)” |
| Sum of target lesion diameters >50 mm, n (%) | “10 (32)” | “14 (47)” | “11 (37)” |
| Sum of target lesion diameters >70 mm, n (%) | “4 (13)” | “8 (27)” | “7 (23)” |
| ECOG PS 0, n (%) | “11 (35)” | “11 (37)” | “10 (33)” |
| ECOG PS 1, n (%) | “20 (65)” | “19 (63)” | “20 (67)” |

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.2-2"></a>

###### First-line 1500 mg weekly cohort by HPV status

| Characteristic | Participants (N = 42) | HPV-positive (n = 12) | HPV-negative (n = 30) |
| --- | --- | --- | --- |
| Age, years, median (range) | “63 (31-84)” | “65 (48-77)” | “63 (31-84)” |
| Male, No. (%) | “30 (71)” | “11 (92)” | “19 (63)” |
| Female, No. (%) | “12 (29)” | “1 (8)” | “11 (37)” |
| White/Caucasian, No. (%) | “34 (81)” | “10 (83)” | “24 (80)” |
| Black or African American, No. (%) | “3 (7)” | “1 (8)” | “2 (7)” |
| Asian, No. (%) | “1 (2)” | “0” | “1 (3)” |
| Multiple races, No. (%) | “1 (2)” | “0” | “1 (3)” |
| Race not reported, No. (%) | “3 (7)” | “1 (8)” | “2 (7)” |
| ECOG performance status 0, No. (%) | “15 (36)” | “4 (33)” | “11 (37)” |
| ECOG performance status 1, No. (%) | “27 (64)” | “8 (67)” | “19 (63)” |
| Oropharynx, No. (%) | “20 (48)” | “12 (100)” | “8 (27)” |
| Oral cavity, No. (%) | “14 (33)” | “0” | “14 (47)” |
| Hypopharynx, No. (%) | “4 (10)” | “0” | “4 (13)” |
| Larynx, No. (%) | “4 (10)” | “0” | “4 (13)” |
| CPS at screening 1-19, No. (%) | “22 (52)” | “7 (58)” | “15 (50)” |
| CPS at screening ≥20, No. (%) | “20 (48)” | “5 (42)” | “15 (50)” |
| Locoregional only, No. (%) | “11 (26)” | “2 (17)” | “9 (30)” |
| Locoregional and distant metastatic, No. (%) | “17 (40)” | “3 (25)” | “14 (47)” |
| Distant metastatic only, No. (%) | “14 (33)” | “7 (58)” | “7 (23)” |
| Sum of target lesion diameters ≤50 mm, No. (%) | “24 (57)” | “8 (67)” | “16 (53)” |
| Sum of target lesion diameters >50 mm, No. (%) | “18 (43)” | “4 (33)” | “14 (47)” |
| Sum of target lesion diameters >70 mm, No. (%) | “11 (26)” | “3 (25)” | “8 (27)” |
| Prior radiotherapy in the LA HNSCC setting, No. (%) | “33 (79)” | “9 (75)” | “24 (80)” |
| Prior platinum-based chemotherapy, No. (%) | “27 (64)” | “12 (100)” | “15 (50)” |

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.2-3"></a>

###### First-line 1500 mg weekly cohort: prior curative-intent therapy

> “At enrollment, 28 patients (66%) had locoregional disease (with or without distant metastases), 39 (93%) had previously received platinum-containing chemotherapy and/or radiation with curative intent, and 22 (52%) had a PD-L1 CPS of 1-19.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.2-4"></a>

###### Dose escalation participants

| Characteristic | Ficerafusp alfa monotherapy (n = 46) | Ficerafusp alfa + pembrolizumab (n = 15) | Total population (N = 61) |
| --- | --- | --- | --- |
| Age (years), median (range) | “61 (43–82)” | “66 (42–81)” | “62 (42–82)” |
| Female, n (%) | “23 (50)” | “5 (33)” | “28 (46)” |
| Male, n (%) | “23 (50)” | “10 (67)” | “33 (54)” |
| ECOG performance status 0, n (%) | “13 (28)” | “4 (27)” | “17 (28)” |
| ECOG performance status 1, n (%) | “33 (72)” | “10 (67)” | “43 (70)” |
| HNSCC, n (%) | “7 (15)” | “7 (47)” | “14 (23)” |
| SCAC, n (%) | “1 (2)” | “8 (53)” | “9 (15)” |
| Number of prior antineoplastic therapies, median (range) | “4 (1–7)” | “2 (1–8)” | “3 (1–8)” |
| Prior anti-EGFR treatment, n (%) | “13 (28)” | “5 (33)” | “18 (30)” |
| Prior anti–PD-(L)1 treatment, n (%) | “21 (46)” | “9 (60)” | “30 (49)” |

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="heading-3.1.2.8.3"></a>

###### 3.1.2.8.3 Efficacy Results

<a id="topic-3.1.2.8.3-1"></a>

###### Dose escalation in advanced solid tumors: response in the combination arm

> “With combination therapy, four of 13 evaluable patients (31%) had a confirmed response, including one with head and neck squamous cell carcinoma refractory to anti–PD-1 therapy and cetuximab.”
> “Four patients (HNSCC, n = 2; SCAC, n = 2) achieved a PR (Fig. 1D), with three of the four demonstrating a duration of response exceeding 2 years (range, 10.1–36.7 months), including one response that was ongoing at data cutoff.”
> “Five patients achieved SD, resulting in an objective response rate of 31% (95% CI, 9%–61%) and a clinical benefit rate of 69% (95% CI, 39%–91%) for the combination.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.8.3-2"></a>

###### Data snapshot of 16 December 2024, 1500 mg weekly cohort: response and 12-month overall survival

> “As of December 16, 2024, 42 pts were treated (71% male, median age: 63 years [range: 31–84]); 39 were efficacy evaluable (EE).”
> “Among the EE pts, the ORR was 54% (21/39; 95% CI: 37–70) in the overall cohort and 64% (18/28; 95% CI: 44–81) in HPV-negative pts.”
> “The 12-month OS rate was 61.5% (95% CI: 44.5–75.7) across the cohort and 60.7% (95% CI: 40.4–76.0) for HPV-negative pts.”

Source: [Chung et al. (2025)](https://ascopubs.org/doi/10.1200/JCO.2025.43.16_suppl.6017)

<a id="topic-3.1.2.8.3-3"></a>

###### Data snapshot of 20 March 2025, 1500 mg weekly cohort: follow-up

> “As of the data snapshot (March 20, 2025), three patients (8%) remained on study treatment and 36 (92%) had discontinued”
> “The median follow-up was 26.3 months (range, 23.9-29.4).”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.3-4"></a>

###### Data snapshot of 20 March 2025, 1500 mg weekly cohort: confirmed response in HPV-negative participants

> “In the HPV-negative subgroup (n = 28), the confirmed ORR was 54% (n = 15; 95% CI, 34 to 73), including six patients (21%) with CR”
> “Of 15 patients with a confirmed response, 12 (80%) had ≥80% target lesion shrinkage, including 3 PRs with complete resolution of target lesions.”
> “The CBR was 86% (n = 24; 95% CI, 67 to 96).”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.3-5"></a>

###### Data snapshot of 20 March 2025, 1500 mg weekly cohort: response by combined positive score and disease pattern in HPV-negative participants

> “Of patients in the HPV-negative subgroup who had a CPS of 1-19 (n = 13) or ≥20 (n = 15), confirmed ORRs were 54% (95% CI, 25 to 81) and 53% (95% CI, 27 to 79), respectively; three additional patients with CPS ≥20 had an unconfirmed response.”
> “Within the HPV-negative subgroup, responses occurred in 15 of 21 patients (71%) with locoregionally recurrent disease (with or without distant metastases) and 7 of 14 patients (50%) with baseline sum of target lesions >50 mm.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.3-6"></a>

###### Data snapshot of 20 March 2025, 1500 mg weekly cohort: duration of and time to response

> “In the HPV-negative subgroup, median DOR was 21.7 months (95% CI, 6.0 to not estimable [NE]; Figs 2B and 2C), and the probability of maintained response at 12 or 18 months was 65% (95% CI, 40 to 90) and 57% (95% CI, 32 to 83), respectively.”
> “Median time to response was 1.4 months (95% CI, 1.4 to 4.7) in the HPV-negative subgroup and 4.1 months (95% CI, 1.3 to 12.0) in the HPV-positive subgroup.”
> “In HPV-negative patients, 56% of responses occurred by the first imaging assessment (6 weeks after treatment) and four patients converted to CR > 6 months after initiating study treatment.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.3-7"></a>

###### Data snapshot of 20 March 2025, 1500 mg weekly cohort: progression-free and overall survival by HPV status

> “In the HPV-negative and HPV-positive subgroups, median (95% CI) PFS was 9.9 (4.4 to 22.7) and 2.0 (1.0 to 10.0) months, and 12-month PFS rates (95% CI) were 48.0% (28.9 to 67.1) and 20.8% (0 to 46.3), respectively (Fig 3).”
> “Median OS (95% CI) in these subgroups was 21.3 (9.9 to NE) and 16.4 (2.6 to 25.7) months, respectively (Fig 2D).”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.3-8"></a>

###### Assessment of April 2025, 1500 mg weekly cohort: 24-month overall survival

> “At the time of the data snapshot, data were too immature to determine 24-month OS rates; however, subsequent OS assessment in April 2025 showed 24-month OS rates in the HPV-negative and HPV-positive subgroups of 46% (95% CI, 23 to 65) and 27% (95% CI, 1.0 to 53.6), respectively.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.3-9"></a>

###### Data snapshot of 20 March 2025, 1500 mg weekly cohort: survival by combined positive score and performance status

> “In subgroups with CPS 1-19 (n = 19) or ≥20 (n = 20), median (95% CI) PFS was 7.4 (2.7 to NE) and 13.4 (2.8 to 23.2) months, and median OS was 22.0 (7.4 to NE) and 20.6 (6.8 to NE) months, respectively.”
> “In patients with ECOG PS 0 (n = 15) or 1 (n = 24), median PFS was 6.9 (2.7 to NE) and 13.4 (4.2 to 26.4) months, and median OS was 20.6 (7.7 to NE) and 26.4 (6.8 to NE) months, respectively.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.3-10"></a>

###### Data snapshot of 20 March 2025, 1500 mg weekly cohort: HPV-positive participants

> “In the HPV-positive subgroup (n = 11), the confirmed ORR was 27% (n = 3; 95% CI, 6 to 61), including two patients (18%) with CR; the CBR was 55% (n = 6; 95% CI, 23 to 83).”
> “In HPV-positive patients classified as smokers (>10 pack-year smoking history; n = 4) or nonsmokers (n = 7), ORR was 75% and 0%, and CBR was 100% and 29%, respectively.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.3-11"></a>

###### Data snapshot of 9 July 2025, 750 mg weekly cohort: response

> “ORR: 57% (17/30); CR: 10% (3/30)”
> “DCR: 83% (25/30)”
> “Median time to response: 1.6 months”
> “Deep response (≥80% tumor shrinkage): 29% (5/17)”
> “Investigator-assessed best overall response per RECIST 1.1”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.8.3-12"></a>

###### Data snapshot of 9 July 2025, 750 mg weekly cohort: response by combined positive score and tumor burden

| Subgroup | Objective response rate |
| --- | --- |
| Combined positive score 1-19 | “73% (8/11)” |
| Combined positive score ≥20 | “47% (9/19)” |
| Sum of target lesion diameters ≤50 mm | “55% (11/20)” |
| Sum of target lesion diameters >50 mm | “60% (6/10)” |
| Sum of target lesion diameters >70 mm | “50% (2/4)” |

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.8.3-13"></a>

###### Data snapshot of 16 December 2025, 2000 mg every-2-weeks cohort: response

| Outcome | Efficacy-evaluable set (N=27) |
| --- | --- |
| Confirmed objective response rate | “48% (13/27)” |
| Disease control rate | “85% (23/27)” |
| Deep response among responders | “77% (10/13)” |
| Complete response rate | “26% (7/27)” |
| Median time to response | “1.6 months” |
| Objective response rate, combined positive score 1-19 | “57% (8/14)” |
| Objective response rate, combined positive score ≥20 | “39% (5/13)” |

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="topic-3.1.2.8.3-14"></a>

###### Data snapshot of 16 December 2025, 750 mg and 1500 mg weekly cohorts: efficacy by cohort

> “As of December 16, 2025, 61 HPV-neg pts were treated in two cohorts (750 mg, n=31; 1500 mg, n=30); 58 pts were efficacy evaluable.”

Source: [Wong et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6040)

| Outcome | Ficerafusp alfa 750 mg plus pembrolizumab (N=30) | Ficerafusp alfa 1500 mg plus pembrolizumab (N=28) |
| --- | --- | --- |
| Confirmed objective response rate/complete response rate, n (%) | “17 (57)/4 (13)” | “15 (54)/6 (21)” |
| Responders with ≥80% shrinkage, n (%) | “8/17 (47)” | “12/15 (80)” |
| Median duration of response, months | “NR” | “21.7” |
| Proportion of responses >12 months, n (%) | “9/17 (53)” | “9/15 (60)” |
| Median progression-free survival, months | “6.9” | “9.9” |

Source: [Wong et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6040)

<a id="topic-3.1.2.8.3-15"></a>

###### Data snapshot of 16 December 2025, three cohorts: confirmed response and pooled depth of response

> “As of December 16, 2025, 85 patients with HPV-negative disease were efficacy evaluable across three cohorts (n=30, n=28, and n=27 at 750mg, 1500mg, and 2000mg doses of ficerafusp alfa, respectively). Among these, the confirmed ORRs were 57%, 54%, and 48%, respectively, including 47%, 80%, and 77% of responders achieving a deep response.”
> “In the pooled efficacy evaluable set the percentage of patients with a deep response was 36%, with tumor regression 0 to <80% was 46%, and no tumor regression was 18%.”

Source: [Kaczmar et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6058)

| Outcome | Tumor regression 0 to <80% (N=39) | Tumor regression ≥80%, deep response (N=31) |
| --- | --- | --- |
| Median duration of response, months | “8.2” | “21.9” |
| Duration of response hazard ratio versus <80% regression (95% CI) | “N/A” | “0.27 [0.10, 0.71]” |
| Median progression-free survival, months | “6.5” | “26.4” |
| Progression-free survival hazard ratio (95% CI) | “N/A” | “0.19 [0.09, 0.40]” |
| Median overall survival, months | “14.9” | “NR” |

Source: [Kaczmar et al. (2026a)](https://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.6058)

<a id="topic-3.1.2.8.3-16"></a>

###### Data snapshot of 31 March 2026, three cohorts: analysis sets and follow-up

> “As of March 31, 2026, 91 patients received the study drug (safety analysis [SA] set) and 85 were evaluable for efficacy (efficacy evaluable [EE] set)”
> “Patient numbers in the SA/EE populations were 31/30, 30/28, and 30/27”
> “Median (95% CI) follow-up was 20 (20-22), 36 (36-43) and 24 (12-27) months”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.3-17"></a>

###### Data snapshot of 31 March 2026, three cohorts: response by cohort

| Outcome | Ficerafusp alfa 750 mg weekly | Ficerafusp alfa 1500 mg weekly | Ficerafusp alfa 2000 mg every 2 weeks |
| --- | --- | --- | --- |
| Confirmed objective response rate (95% CI) | “57% (37%-74%)” | “54% (34%-72%)” | “48% (29%-68%)” |
| Deep response among responders | “47% (8/17)” | “80% (12/15)” | “77% (10/13)” |

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.3-18"></a>

###### Data snapshot of 31 March 2026, three cohorts: company summary of efficacy by cohort

| Outcome | Ficerafusp alfa 750 mg weekly (n=30) | Ficerafusp alfa 1500 mg weekly (n=28) | Ficerafusp alfa 2000 mg every 2 weeks (n=27) |
| --- | --- | --- | --- |
| Confirmed overall response rate | “57%” | “54%” | “48%” |
| Complete response rate | “13%” | “25%” | “30%” |
| Deep (≥80%) responses | “47%” | “80%” | “77%” |
| Median time to response | “1.6 months” | “1.4 months” | “1.6 months” |
| Median duration of response | “NR (>16.6 months)” | “21.7 months” | “NR (>12.8 months)” |
| Median progression-free survival | “6.9 months” | “9.9 months” | “12.7 months” |
| Median overall survival | “NM (>19.4 months)” | “21.3 months” | “NM (>12.7 months; >23.6 months in patients with > 2-year follow-up)” |

Source: [Bicara Therapeutics three-year overall survival announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated)

<a id="topic-3.1.2.8.3-19"></a>

###### Data snapshot of 31 March 2026, 1500 mg weekly cohort: response, duration of response, and 3-year overall survival

> “Response: Confirmed ORR of 54% (CR in 25%) with a rapid median time to response of 1.4 months”
> “After a median follow-up of 36 months, median DOR in the 1500 mg QW cohort was of 21.7 months, with 10% of patients (n=3) remaining on active treatment.”
> “At a median follow-up of 36 months, the 1500 mg QW cohort achieved a clinically meaningful median OS of 21.3 months; the tail of the curve reflects durable long-term survival, highlighted by a landmark 3-year OS rate of 31%”
> “Survival: Median OS of 21.3 months with an estimated 31% of patients alive at 3 years”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.3-20"></a>

###### Data snapshot of 31 March 2026, three cohorts: progression-free and overall survival with confidence intervals

| Outcome | Ficerafusp alfa 750 mg weekly | Ficerafusp alfa 1500 mg weekly | Ficerafusp alfa 2000 mg every 2 weeks |
| --- | --- | --- | --- |
| Median progression-free survival (95% CI), months | “6.9 (4.6-NE)” | “9.9 (4.4-22.7)” | “12.7 (4.9-NE)” |
| Median overall survival (95% CI), months | “Not mature” | “21.3 (9.9-33.6)” | “Not mature” |

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.3-21"></a>

###### Data snapshot of 31 March 2026, three cohorts: confirmed response by combined positive score, tumor burden, and extent of disease

| Subgroup, % (n/N) | Ficerafusp alfa 750 mg weekly (n=30) | Ficerafusp alfa 1500 mg weekly (n=28) | Ficerafusp alfa 2000 mg every 2 weeks (n=27) |
| --- | --- | --- | --- |
| Combined positive score 1-19 | “73 (8/11)” | “54 (7/13)” | “57 (8/14)” |
| Combined positive score ≥20 | “47 (9/19)” | “53 (8/15)” | “38 (5/13)” |
| Sum of target lesion diameters ≤50 mm | “55 (11/20)” | “53 (8/15)” | “53 (9/17)” |
| Sum of target lesion diameters >50 mm | “60 (6/10)” | “54 (7/13)” | “40 (4/10)” |
| Sum of target lesion diameters >70 mm | “50 (2/4)” | “43 (3/7)” | “33 (2/6)” |
| Locoregional disease only | “38 (6/16)” | “62 (5/8)” | “50 (7/14)” |
| Distant metastatic disease only | “100 (5/5)” | “29 (2/7)” | “40 (2/5)” |
| Locoregional and distant metastatic disease | “67 (6/9)” | “62 (8/13)” | “50 (4/8)” |

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.3-22"></a>

###### Data snapshot of 31 March 2026, three cohorts pooled: outcomes by depth of response

> “A pooled analysis of the EE population across all three dose cohorts evaluated whether a deep response (≥80% shrinkage) predicted prolonged DOR, PFS, and OS compared with standard partial response (PR <80%).”
> “Deep response (≥80% tumor shrinkage) was associated with substantially prolonged DOR compared with PR <80% (HR, 0.31 [95% CI, 0.11-0.84])”
> “65% reduction in the risk of disease progression or death compared with PR <80% (HR, 0.35 [95% CI, 0.15-0.91)”
> “reducing the risk of death by 63% (HR, 0.37 [95% CI, 0.13–1.10])”
> “HRs (95% CI) with additional baseline covariate adjustment are shown.”

Source: [Kaczmar et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Kaczmar_2026_ASCO_Poster-layout_Deep-response_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.3-23"></a>

###### Data snapshot of 31 March 2026, three cohorts pooled: median duration of response, progression-free survival, and overall survival by best response

| Best response group | Median duration of response (95% CI), months | Median progression-free survival (95% CI), months | Median overall survival (95% CI), months |
| --- | --- | --- | --- |
| Deep response (n=30) | “31.6 (21.6-NE)” | “36.9 (22.7-NE)” | “Not reached (26.3-NE)” |
| Partial response <80% (n=15) | “8.2 (4.0-NE)” | “10.9 (5.6-NE)” | “33.6 (10.9-NE)” |

Source: [Kaczmar et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Kaczmar_2026_ASCO_Poster-layout_Deep-response_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.3-24"></a>

###### Data snapshot of 31 March 2026, three cohorts pooled: progression-free and overall survival with stable or progressive disease

| Best response group | Median progression-free survival (95% CI), months | Median overall survival (95% CI), months |
| --- | --- | --- |
| Stable disease (n=26) | “5.8 (3.6-6.8)” | “11.3 (9.0-20.6)” |
| Progressive disease (n=14) | “1.4 (1.3-1.5)” | “7.3 (2.4-17.1)” |

Source: [Kaczmar et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Kaczmar_2026_ASCO_Poster-layout_Deep-response_FINAL-APPROVED.pdf)

<a id="heading-3.1.2.8.4"></a>

###### 3.1.2.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.2.8.4-1"></a>

###### Patient-reported outcomes not assessed in the 1500 mg weekly expansion cohort

> “patient-reported outcomes were not assessed”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="heading-3.1.2.8.5"></a>

###### 3.1.2.8.5 Safety Results

<a id="topic-3.1.2.8.5-1"></a>

###### Dose escalation in advanced solid tumors: combination arm

> “The MTD was not reached in either cohort.”
> “TRAEs were reported for 87% (40 of 46) and 87% (13 of 15) of patients treated with ficerafusp alfa monotherapy and ficerafusp alfa in combination with pembrolizumab, respectively.”
> “For ficerafusp alfa in combination with pembrolizumab, the most common TRAEs were acneiform dermatitis (73%; 11 of 15), fatigue (53%; eight of 15), epistaxis (40%; six of 15), pruritus (40%; six of 15), and maculopapular rash (40%; six of 15).”
> “For ficerafusp alfa in combination with pembrolizumab, serious TRAEs included grade 3 anemia (n = 1), grade 3 stomatitis with grade 3 atrial fibrillation (n = 1), and grade 3 stomatitis with grade 3 pneumonitis (n = 1).”
> “Two patients treated with ficerafusp alfa in combination with pembrolizumab discontinued both drugs because of grade 3 reactive lichen planus and grade 3 atrial fibrillation, respectively. No grade 4 TRAEs or treatment-related deaths were observed in either cohort.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.8.5-2"></a>

###### Data snapshot of 20 March 2025, 1500 mg weekly cohort: summary of treatment-related adverse events

| Safety outcome | Participants (N = 42), No. (%) |
| --- | --- |
| Grade 3 or 4 treatment-related adverse event | “20 (48)” |
| Treatment-related adverse event leading to ficerafusp alfa discontinuation | “5 (12)” |
| Treatment-related adverse event leading to death | “0” |

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.5-3"></a>

###### Data snapshot of 20 March 2025, 1500 mg weekly cohort: treatment-related adverse events by grade

| Treatment-related adverse event | Any grade | Grade 1/2 | Grade 3 | Grade 4 |
| --- | --- | --- | --- | --- |
| Any treatment-related adverse event | “40 (95)” | “20 (48)” | “19 (45)” | “1 (2)” |
| Dermatitis acneiform | “32 (76)” | “27 (64)” | “5 (12)” | “0” |
| Fatigue | “19 (45)” | “18 (43)” | “1 (2)” | “0” |
| Pruritus | “18 (43)” | “17 (40)” | “1 (2)” | “0” |
| Anemia | “15 (36)” | “9 (21)” | “6 (14)” | “0” |
| Stomatitis | “11 (26)” | “9 (21)” | “2 (5)” | “0” |
| Infusion-related reaction | “8 (19)” | “7 (17)” | “1 (2)” | “0” |
| Epistaxis | “6 (14)” | “6 (14)” | “0” | “0” |
| Gingival bleeding | “6 (14)” | “6 (14)” | “0” | “0” |
| Colitis | “5 (12)” | “2 (5)” | “3 (7)” | “0” |
| Tracheal hemorrhage | “2 (5)” | “1 (2)” | “1 (2)” | “0” |
| Pericarditis | “1 (2)” | “0” | “0” | “1 (2)” |

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.5-4"></a>

###### Data snapshot of 20 March 2025, 1500 mg weekly cohort: overall incidence, interruptions, and discontinuations

> “Patients received a median of six cycles (IQR, 3-12) of ficerafusp alfa and six cycles (IQR, 3-10) of pembrolizumab.”
> “Grade 3 TRAEs occurred in 19 patients (45%), and one patient (2%) had a grade 4 TRAE. The most common grade ≥3 TRAEs were anemia (six [14%]) and acneiform dermatitis (five [12%]); all other grade ≥3 TRAEs occurred in ≤3 patients. No fatal TRAEs were reported.”
> “After TRAEs, ficerafusp alfa treatment was interrupted in 20 patients (48%), due to grade 3 TRAEs in 14 patients (most frequently anemia [n = 4], acneiform dermatitis [n = 4], and colitis [n = 3]). TRAEs led to ficerafusp alfa discontinuation in five patients (12%). No TRAE led to discontinuation in more than one patient.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.5-5"></a>

###### Data snapshot of 20 March 2025, 1500 mg weekly cohort: dermatologic events including acneiform dermatitis

> “Dermatologic TRAEs occurred at any grade in 36 patients (86%); the most frequent were acneiform dermatitis (32 [76%]) and pruritus (18 [43%]). Eight patients (19%) had a grade 3 dermatologic TRAE. Ficerafusp alfa was interrupted because of dermatologic TRAEs in eight patients (19%). Supportive care administered by investigators included topical steroid and antibiotics. No patient discontinued treatment because of dermatitis acneiform or rash TRAEs.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.5-6"></a>

###### Data snapshot of 20 March 2025, 1500 mg weekly cohort: bleeding events

> “Bleeding-related TRAEs occurred at any grade in 14 patients (33%); the most frequent were epistaxis (six [14%]), gingival bleeding (six [14%]), and hematuria (four [10%]). One patient (2%) had a grade 3 bleeding-related TRAE; none reached grade ≥4. Bleeding-related TRAEs led to interruption of ficerafusp alfa in two patients (5%); no discontinuations occurred.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.5-7"></a>

###### Data snapshot of 20 March 2025, 1500 mg weekly cohort: anemia and infusion-related reactions

> “Anemia TRAEs occurred at any grade in 15 patients (36%) and reached grade 3 in six (14%); no grade ≥4 events occurred. Anemia TRAEs led to interruption of ficerafusp alfa in four patients (10%) and discontinuation in two patients (5%). Supportive care administered by investigators included iron supplementation and transfusion. IRR TRAEs occurred in eight patients (19%), including grade 3 IRR in one patient (2%), and led to ficerafusp alfa interruption in two (5%); no discontinuations occurred.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.5-8"></a>

###### Data snapshot of 20 March 2025, 1500 mg weekly cohort: treatment-emergent adverse events and deaths

| Safety outcome | Participants (N = 42), n (%) |
| --- | --- |
| Grade ≥3 treatment-emergent adverse event | “33 (79)” |
| Treatment-emergent adverse event leading to ficerafusp alfa discontinuation | “9 (21)” |
| Treatment-emergent adverse event leading to death | “3 (7)” |

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.8.5-9"></a>

###### Data snapshot of 9 July 2025, 750 mg weekly cohort: treatment-related adverse events

| Preferred term, n (%) | Any grade (N=31) | Grade 3 (N=31) |
| --- | --- | --- |
| Any treatment-related adverse event | “31 (100)” | “13 (42)” |
| Dermatitis acneiform | “26 (84)” | “1 (3)” |
| Pruritus | “12 (39)” | “1 (3)” |
| Stomatitis | “10 (32)” | “3 (10)” |
| Epistaxis | “10 (32)” | “1 (3)” |
| Anemia | “8 (26)” | “3 (10)” |
| Hypokalemia | “7 (23)” | “2 (6)” |

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.8.5-10"></a>

###### Data snapshot of 9 July 2025, 750 mg weekly cohort: discontinuations and deaths

| Safety outcome | Safety set (N=31) |
| --- | --- |
| Treatment-related adverse event leading to ficerafusp alfa discontinuation | “2 (6%)” |

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

> “No treatment-related deaths were reported”
> “n=1 each for TEAEs leading to dose reduction and discontinuation.”

Source: [Kaczmar et al. (2025)](https://www.bicara.com/wp-content/uploads/2025/12/750-mg-ESMO-Asia-Congress-2025-12.6.25.pdf)

<a id="topic-3.1.2.8.5-11"></a>

###### Data snapshot of 16 December 2025, 2000 mg every-2-weeks cohort: treatment-emergent adverse events related to ficerafusp alfa

| Event | Any grade (N=30) | Grade 3 (N=30) |
| --- | --- | --- |
| Any related treatment-emergent adverse event | “29 (97%)” | “16 (53%)” |
| Dermatitis acneiform | “24 (80%)” | “3 (10%)” |
| Anemia | “14 (47%)” | “8 (27%)” |
| Stomatitis | “11 (37%)” | “3 (10%)” |
| Pruritus | “11 (37%)” | “1 (3%)” |
| Nausea | “9 (30%)” | “1 (3%)” |

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="topic-3.1.2.8.5-12"></a>

###### Data snapshot of 16 December 2025, 2000 mg every-2-weeks cohort: discontinuations, grade 4 and 5 events, and deaths

| Safety outcome | Safety set (N=30) |
| --- | --- |
| Treatment-related adverse event leading to ficerafusp alfa discontinuation | “3 (10%)” |

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

> “1 patient had a grade 4 event (hypokalemia); no grade 5 events occurred.”
> “No treatment-related deaths were reported”

Source: [Zandberg et al. (2026)](https://www.bicara.com/wp-content/uploads/2026/02/Zandberg_2026_MHNCS_Pres_2000-mg-Cohort_Edited.pdf)

<a id="topic-3.1.2.8.5-13"></a>

###### Data snapshot of 31 March 2026, three cohorts: treatment-related adverse events by grade and cohort

| Preferred term, n (%) | 750 mg weekly (N=31), any grade | 750 mg weekly, grade 3 | 1500 mg weekly (N=30), any grade | 1500 mg weekly, grade 3 | 2000 mg every 2 weeks (N=30), any grade | 2000 mg every 2 weeks, grade 3 |
| --- | --- | --- | --- | --- | --- | --- |
| Any treatment-related adverse event | “31 (100)” | “11 (35)” | “28 (93)” | “15 (50)” | “29 (97)” | “16 (53)” |
| Dermatitis acneiform | “27 (87)” | “1 (3)” | “23 (77)” | “4 (13)” | “24 (80)” | “3 (10)” |
| Pruritus | “13 (42)” | “1 (3)” | “16 (53)” | “1 (3)” | “11 (37)” | “1 (3)” |
| Anemia | “8 (26)” | “3 (10)” | “13 (43)” | “7 (23)” | “15 (50)” | “8 (27)” |
| Fatigue | “13 (42)” | “0 (0)” | “11 (37)” | “1 (3)” | “12 (40)” | “1 (3)” |
| Stomatitis | “13 (42)” | “4 (13)” | “8 (27)” | “0” | “11 (37)” | “3 (10)” |
| Epistaxis | “11 (35)” | “1 (3)” | “5 (17)” | “0” | “12 (40)” | “0” |
| Mouth bleeding | “8 (26)” | “1 (3)” | “0” | “0” | “4 (13)” | “0” |
| Infusion-related reaction | “6 (19)” | “1 (3)” | “4 (13)” | “1 (3)” | “7 (23)” | “0” |

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.8.5-14"></a>

###### Data snapshot of 31 March 2026, three cohorts: discontinuations, grade 4 events, and deaths

> “Dose discontinuations due to ficerafusp alfa-related TEAEs in the 750mg QW, 1500mg QW and 2000mg Q2W dose cohorts were reported in 2 (6%), 3 (10%) and 2 (7%) patients, respectively. No patient had a grade 5 TEAE related to ficerafusp alfa.”
> “1 patient had grade 4 hypokalemia.”
> “1 patient had grade 4 pericarditis.”
> “No new safety signals were observed in any dose cohort with longer follow-up”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="heading-3.1.2.9"></a>

##### 3.1.2.9 Study Limitations

<a id="topic-3.1.2.9-1"></a>

###### Summary

BCA101X1101 is an open-label, nonrandomized, single-arm phase 1/1b trial with investigator-assessed response; the authors state that the single-arm design makes it “difficult to isolate the contribution of individual treatment components”, and comparisons with KEYNOTE-048 are cross-trial. The 1500 mg weekly cohort enrolled participants in the United States and Canada only, did not assess patient-reported outcomes, and did not routinely collect subsequent therapy. The three first-line dose cohorts were analyzed as separate HPV-negative expansion cohorts of 30, 28, and 27 evaluable participants under a Simon two-stage design, with PD-L1 CPS assessed locally by 22C3 “or other validated assay” and HPV-positive participants of the 1500 mg cohort excluded from the integrated analysis. Duration of response and OS are immature in the 750 mg weekly and 2000 mg every 2 weeks cohorts; in the 2000 mg cohort, 12 of 27 evaluable participants had a median follow-up of 11.7 months. The depth-of-response analysis was post hoc, with small subgroups and a threshold that is not validated. The dose-escalation results come from 15 combination-arm participants with heterogeneous tumors and prior therapy.

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027); [Bicara Therapeutics three-year overall survival announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated); [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf); [Kaczmar et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Kaczmar_2026_ASCO_Poster-layout_Deep-response_FINAL-APPROVED.pdf); [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="topic-3.1.2.9-2"></a>

###### Single-arm design, limited geographic scope, and missing subsequent-therapy data

> “Limitations of this study include its single-arm design, which makes it difficult to isolate the contribution of individual treatment components. Although baseline characteristics of HPV-negative and HPV-positive subgroups were generally well balanced, the study design and limited geographic scope (the United States and Canada) may have introduced bias, and patient-reported outcomes were not assessed. Additionally, information on subsequent treatment after study discontinuation was not collected routinely and could not be analyzed.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.9-3"></a>

###### Open-label, nonrandomized design with investigator-assessed response

> “This open-label, multicenter, prospective, nonrandomized, first-in-human, phase I/Ib study”
> “investigator-assessed according to RECIST v1.1”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

<a id="topic-3.1.2.9-4"></a>

###### Cross-trial comparisons with historical controls

> “With the caveats of cross-trial comparisons, the ORR of 54% with ficerafusp alfa plus pembrolizumab in the HPV-negative subgroup compares favorably with the ORR of 19% with pembrolizumab monotherapy in patients with CPS ≥1 in the KEYNOTE-048 phase III trial.”

Source: [Hanna et al. (2026)](https://ascopubs.org/doi/10.1200/JCO-25-02027)

> “No head-to-head studies have been conducted, and cross-trial comparisons differences in molecule composition, trial design, and patient population and characteristics.”

Source: [Bicara Therapeutics three-year overall survival announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/ficerafusp-alfa-plus-pembrolizumab-demonstrated-differentiated)

<a id="topic-3.1.2.9-5"></a>

###### Immature duration of response and survival in the 750 mg and 2000 mg cohorts

> “While DOR data are immature for the 750 mg QW and 2000 mg Q2W cohorts”
> “Data maturation reflects a bimodal enrollment distribution: in the initial 15 EE patients (median follow-up, 27 months), median OS was not reached (95% CI, 9-NE; median has surpassed 23.6 months). The remaining 12 EE patients had a median follow-up of 11.7 months.”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.9-6"></a>

###### Local PD-L1 testing and exclusion of HPV-positive participants from the dose-cohort analyses

> “The 1500 mg QW cohort also enrolled HPV-positive patients, who were not included in the current analysis.”
> “PD-L1 CPS was assessed locally in archival or fresh samples using the 22C3 immunohistochemistry or other validated assay.”

Source: [Wong et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Wong_2026_ASCO_Poster-Layout_LT-results_v13_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.9-7"></a>

###### Post hoc depth-of-response analysis with an unvalidated threshold

> “This was a post hoc exploratory analysis limited by small sample sizes in each subgroup”
> “Depth of response categories are not validated and a unified standard threshold for deep response has not been established”

Source: [Kaczmar et al. (2026b)](https://www.bicara.com/wp-content/uploads/2026/05/Kaczmar_2026_ASCO_Poster-layout_Deep-response_FINAL-APPROVED.pdf)

<a id="topic-3.1.2.9-8"></a>

###### Small sample and heterogeneous population in dose escalation

> “The findings presented here should be interpreted with recognition of the limited sample size and the heterogeneity of the population under study in this phase I clinical trial.”

Source: [Hernando-Calvo et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12616243/)

<a id="heading-3.1.3"></a>

#### 3.1.3 FORTIFI-FLEX

<a id="heading-3.1.3.1"></a>

##### 3.1.3.1 Objective

<a id="topic-3.1.3.1-1"></a>

###### Study aim in the ClinicalTrials.gov record

> “The study aims to demonstrate that the antitumor activity of an alternative dosing regimen of ficerafusp alfa in combination with pembrolizumab is comparable to the weekly ficerafusp alfa regimen in 1L PD-L1-positive, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC).”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.1-2"></a>

###### Main and secondary objectives in the EU trial record

> “To evaluate whether the antitumor activity of the once every 3 weeks (Q3W) alternative ficerafusp alfa dosing regimen is maintained when compared to the standard weekly dosing regimen after randomization”
> “To evaluate the pharmacokinetics of ficerafusp alfa”
> “To further evaluate antitumor activity during the maintenance phase for participants receiving the alternative and standard dosing regimens”
> “To evaluate antitumor activity for the overall dosing regimen across the full study treatment course, including both loading and maintenance phases”
> “To evaluate the safety and tolerability profile during the maintenance phase for participants receiving the alternative and standard maintenance dosing regimens”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="topic-3.1.3.1-3"></a>

###### Study purpose in the quarterly report

> “We expect to have results from this study by the time of a potential U.S. approval in 1L R/M HPV-negative HNSCC.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="heading-3.1.3.2"></a>

##### 3.1.3.2 Location and Study Date

<a id="topic-3.1.3.2-1"></a>

###### Study dates in the ClinicalTrials.gov record

| Study characteristic | Quoted record |
| --- | --- |
| Study start (estimated) | “2026-09” |
| Primary completion (estimated) | “2028-03” |
| Study completion (estimated) | “2029-03” |
| First posted | “2026-09-08” |
| Sites | “This study has 7 locations” |

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.2-2"></a>

###### Study initiation in the quarterly report

> “In August 2026, we announced the initiation of FORTIFI-FLEX, a randomized clinical study that will evaluate ficerafusp alfa in combination with pembrolizumab, administered as a 12-week loading dose of 1500mg QW followed by maintenance dosing of 2250mg every three weeks as compared to 1500mg QW of ficerafusp alfa, each in combination with pembrolizumab.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="heading-3.1.3.3"></a>

##### 3.1.3.3 Study Design

<a id="topic-3.1.3.3-1"></a>

###### Open-label randomized phase 2 design in the ClinicalTrials.gov record

> “A Multicenter, Open-label, Randomized Phase 2 Study Evaluating Continuous Weekly Dosing of Ficerafusp Alfa (BCA101) in Combination With Pembrolizumab Versus an Alternative Ficerafusp Alfa Dosing Regimen for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma”
> “Participants who remain on study without progression at the end of the loading phase will enter the maintenance phase and will be randomized 2:1 to one of the following arms:”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.3-2"></a>

###### Study design in the second-quarter results press release

> “Initiated FORTIFI-FLEX, a randomized, open-label, clinical study that will evaluate ficerafusp alfa in combination with pembrolizumab, administered as a 12-week loading dose of 1500mg weekly (QW) followed by maintenance dosing of 2250mg every three weeks (Q3W).”

Source: [Bicara Therapeutics second quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-second-quarter-2026-progress-and)

<a id="topic-3.1.3.3-3"></a>

###### Study schema in the corporate presentation

> “Loading phase”
> “Maintenance phase”
> “FICERA 2250mg Q3W”
> “1L R/M HPV-negative HNSCC”

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="heading-3.1.3.4"></a>

##### 3.1.3.4 Eligibility Criteria

<a id="topic-3.1.3.4-1"></a>

###### Inclusion criteria in the ClinicalTrials.gov record

> “Age ≥18 years on the day the Informed Consent Form is signed.”
> “Histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: primary tumor location of paranasal sinuses and nasopharynx, any histology are excluded.”
> “No prior systemic therapy administered in the R or M setting; and completed systemic therapy >6 months prior if given as part of multimodal treatment for locoregionally advanced disease in the adjuvant or definitive setting.”
> “Archival tumor tissue or willing to undergo pretreatment biopsy at Screening if archival tissue is insufficient or unavailable.”
> “PD-L1 CPS ≥1.”
> “Measurable disease based on RECIST 1.1.”
> “Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.”
> “Adequate organ function, as defined in the protocol.”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.4-2"></a>

###### Exclusion criteria in the ClinicalTrials.gov record

> “Disease suitable for local therapy administered with curative intent.”
> “Prior treatment with anti-TGFβ therapy.”
> “Prior therapy with an anti-EGFR antibody (exception: radio sensitizing agents and multimodal treatment for locoregionally advanced disease).”
> “Prior history of Grade ≥2 intolerance or hypersensitivity reaction to anti-EGFR therapy or other murine proteins.”
> “Prior therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.”
> “Progressive disease <6 months from completion of curative intent systemic therapy for locoregionally advanced HNSCC.”
> “Life expectancy less than 3 months.”
> “Known active central nervous system metastases, history of spinal cord compression from tumor involvement, a history of carcinomatous meningitis, or leptomeningeal disease are excluded.”
> “Current active major bleeding, or a recent major bleeding episode within 4 weeks prior to enrollment.”
> “Subject participated in another clinical study or received treatment with another investigational drug must wait at least 5 half-lives of the treatment received or 4 weeks (whichever is shorter) following prior therapy.”
> “Active autoimmune disease requiring systemic treatment in the past 2 years.”
> “Subjects with chronic hepatitis B virus (HBV) infection with active disease who meet the criteria for anti-HBV therapy and are not on a suppressive antiviral therapy prior to initiation of study treatment.”
> “Subjects with a known history of hepatitis C virus (HCV) who have not completed curative antiviral treatment or have an HCV viral load above the limit of quantification at Screening.”
> “Known history of human immunodeficiency virus (HIV).”
> “Receipt of any organ transplantation, including autologous and allogeneic stem cell transplantation, with the exception of transplants that do not require immunosuppression.”
> “Known to be diagnosed and/or treated for any other additional malignancy within 2 years prior to randomization with the exception of the following: curatively treated basal cell carcinoma or squamous cell carcinoma of the skin, and curatively resected in situ cervical cancer, and curatively resected in situ breast cancer, and low-risk early stage prostate cancer.”
> “Any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive medication within 7 days prior to the first dose of study treatment, except for topical, intranasal, intrabronchial, or ocular steroids.”
> “Use of a live or live attenuated vaccine within 4 weeks prior to Screening.”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.4-3"></a>

###### HPV status determination in the EU trial record

> “Participant has histologically or cytologically confirmed R or M HNSCC. Eligible primary tumor locations are oral cavity, hypopharynx, larynx, or oropharynx (with documented HPV-negative disease if presenting with OPSCC). Note: Primary tumor locations of paranasal sinuses and nasopharynx or tumor of any other histology are excluded.”
> “Participants presenting with primary tumor location in oropharynx must have documentation of HPV-negative disease as determined by a validated test.”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="topic-3.1.3.4-4"></a>

###### PD-L1 assay and testing in the EU trial record

> “Participant is eligible to receive pembrolizumab as frontline monotherapy with documented tumor PD-L1 CPS ≥1 (by PD-L1 immunohistochemistry [IHC] 22C3), determined locally or centrally.”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="topic-3.1.3.4-5"></a>

###### Prior-therapy criteria in the EU trial record

> “No prior systemic therapy administered in the R  or M setting. Systemic therapy completed >6 months prior to signing ICF if given as part of multimodal treatment for locoregionally advanced disease is allowed.”
> “Prior therapy with an anti-EGFR antibody”
> “Prior (neoadjuvant and/or adjuvant) therapy with an immune checkpoint inhibitor completed within 6 months prior to study treatment initiation.”
> “PD (radiologically or pathologically confirmed) <6 months from completion of curative intent platinum-containing systemic therapy for locoregionally advanced HNSCC.”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="topic-3.1.3.4-6"></a>

###### Measurable disease and performance status in the EU trial record

> “Participant has measurable disease based on RECIST 1.1 as determined by BICR.”
> “Participant has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="heading-3.1.3.5"></a>

##### 3.1.3.5 Treatment

<a id="topic-3.1.3.5-1"></a>

###### Treatment arms in the ClinicalTrials.gov record

| Arm | Quoted regimen |
| --- | --- |
| Arm A, loading phase | “Loading phase (12 weeks): Ficerafusp alfa 1500 mg QW (standard dose) + pembrolizumab 200 mg Q3W.” |
| Arm A, maintenance phase | “Maintenance phase: Ficerafusp alfa 2250 mg Q3W (alternative dose) + pembrolizumab 200 mg Q3W.” |
| Arm B | “Continuous ficerafusp alfa 1500 mg QW (standard dose) + pembrolizumab 200 mg Q3W.” |

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.5-2"></a>

###### Loading regimen for all participants in the ClinicalTrials.gov record

> “All participants will receive ficerafusp alfa 1500 mg once weekly (QW in combination with pembrolizumab 200 mg every three weeks (Q3W) for 12 weeks (loading phase).”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="heading-3.1.3.6"></a>

##### 3.1.3.6 Study Outcomes

<a id="heading-3.1.3.6.1"></a>

###### 3.1.3.6.1 Rationale for Using Progression-free Survival Rate in the Maintenance Phase as the Primary Endpoint

<a id="topic-3.1.3.6.1-1"></a>

###### Primary endpoint in the ClinicalTrials.gov record

| Primary endpoint | Quoted record |
| --- | --- |
| Measure | “Proportion of participants in maintenance phase who are progression-free as assessed by blinded independent central review (BICR) per RECIST 1.1 and alive.” |
| Time frame | “Approximately 9 months.” |

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.6.1-2"></a>

###### Primary endpoint in the EU trial record

> “Proportion of participants in maintenance phase who are progression-free as assessed by blinded independent central review per Response Evaluation Criteria in Solid Tumors 1.1 and alive after randomization”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="topic-3.1.3.6.1-3"></a>

###### Secondary endpoints in the ClinicalTrials.gov record

> “Serum exposure of ficerafusp alfa.”
> “Objective response rate (ORR) per RECIST 1.1 by blinded independent central review (BICR).”
> “Disease control rate (DCR) per RECIST 1.1 by blinded independent central review (BICR)”
> “Clinical Benefit Rate (CBR) per RECIST 1.1 by blinded independent central review (BICR)”
> “Duration of Response (DOR) per RECIST 1.1 by blinded independent central review (BICR).”
> “Progression-free survival (PFS) per RECIST 1.1 by blinded independent central review (BICR).”
> “Overall Survival (OS)”
> “Time to Response (TTR) per RECIST 1.1 by blinded independent central review (BICR)”
> “Deep Response Rate by blinded independent central review (BICR)”
> “Time to maximum tumor shrinkage”
> “Incidence of ≥Grade 3 TEAEs”
> “Incidence of Serious adverse events (SAEs)”
> “Incidence of Adverse events (AEs) leading to dose modifications (dose reduction, interruption, dose held, or discontinuation)”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.6.1-4"></a>

###### Deep response definition in the EU trial record

> “Deep response rate among responders (defined as best target lesion shrinkage ≥80%)”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="topic-3.1.3.6.1-5"></a>

###### Regulatory basis for the alternate regimen in company documents

> “Based on recent discussions with the U.S. Food and Drug Administration (FDA), the company plans to initiate a randomized clinical study that will evaluate ficerafusp alfa in combination with pembrolizumab, administered as a 12-week loading dose of 1500mg weekly (QW) followed by maintenance dosing of 2250mg every three weeks (Q3W).”

Source: [Bicara Therapeutics first quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-first-quarter-2026-financial-results)

> “The primary endpoint will evaluate the proportion of patients in the maintenance phase who are progression-free.”

Source: [Bicara Therapeutics Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026072169/bcax-20260930.htm)

<a id="topic-3.1.3.6.1-6"></a>

###### Basis in the every-two-week expansion cohort in the annual report

> “The purpose of this expansion cohort was to further support the pharmacokinetic and pharmacodynamic profile of ficerafusp alfa, particularly its eight-day half-life, and the development of a less frequent dose regimen.”
> “In conjunction with the presentation of those data, we announced plans to develop ficerafusp alfa with a loading and every-three-week maintenance schedule and aim to achieve regulatory alignment to enable data generation by potential U.S. approval.”

Source: [Bicara Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/2023658/000162828026022010/bcax-20251231.htm)

<a id="topic-3.1.3.6.1-7"></a>

###### FDA dose-optimization guidance on activity endpoints for dosage comparisons

> “Relevant measures of activity may include tumor assessment-based endpoints (e.g., overall response rate: ORR, progression-free survival: PFS), and other tissue, blood, or imaging-based endpoints.”
> “The trial should be sized to allow for sufficient assessment of safety and antitumor activity for each dosage.”

Source: [FDA (2024)](https://www.fda.gov/media/164555/download)

<a id="topic-3.1.3.6.1-8"></a>

###### FDA endpoint guidance on progression-free survival

> “PFS can reflect tumor growth and be assessed before the determination of a survival benefit.”

Source: [FDA (2018)](https://www.fda.gov/media/71195/download)

<a id="heading-3.1.3.7"></a>

##### 3.1.3.7 Statistical Analysis Description

<a id="heading-3.1.3.7.1"></a>

###### 3.1.3.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.3.7.1-1"></a>

###### Planned enrollment in the ClinicalTrials.gov record

> “Enrollment (Estimated) 160”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.7.1-2"></a>

###### Planned enrollment in the corporate presentation

> “(n=150-200)”

Source: [Bicara Therapeutics presentation (2026)](https://ir.bicara.com/static-files/a3b76471-7043-4563-a072-1fd4630515e4)

<a id="heading-3.1.3.7.2"></a>

###### 3.1.3.7.2 Description of Analysis Sets

<a id="topic-3.1.3.7.2-1"></a>

###### Maintenance-phase randomization in the ClinicalTrials.gov record

> “Participants who remain on study without progression at the end of the loading phase will enter the maintenance phase and will be randomized 2:1 to one of the following arms:”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

<a id="topic-3.1.3.7.2-2"></a>

###### Maintenance-phase and overall-course analyses in the EU trial record

> “To further evaluate antitumor activity during the maintenance phase for participants receiving the alternative and standard dosing regimens”
> “To evaluate antitumor activity for the overall dosing regimen across the full study treatment course, including both loading and maintenance phases”
> “To evaluate the safety and tolerability profile for the overall dosing regimen across the full study treatment course, including both loading and maintenance phase”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="heading-3.1.3.8"></a>

##### 3.1.3.8 Results

<a id="heading-3.1.3.8.1"></a>

###### 3.1.3.8.1 Participant Disposition

<a id="topic-3.1.3.8.1-1"></a>

###### Enrollment status in the third-quarter results press release

> “Continue to enroll FORTIFI-FLEX, a randomized, open-label clinical trial that is evaluating ficerafusp alfa, administered as a 12-week loading dose of 1500mg weekly (QW) followed by maintenance dosing of 2250mg every three weeks (Q3W) as compared to 1500mg QW of ficerafusp alfa, each in combination with pembrolizumab.”

Source: [Bicara Therapeutics third quarter 2026 results announcement (2026)](https://ir.bicara.com/news-releases/news-release-details/bicara-therapeutics-reports-third-quarter-2026-financial-results)

<a id="heading-3.1.3.8.2"></a>

###### 3.1.3.8.2 Baseline Characteristics

No evidence found.

<a id="heading-3.1.3.8.3"></a>

###### 3.1.3.8.3 Efficacy Results

No evidence found.

<a id="heading-3.1.3.8.4"></a>

###### 3.1.3.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.3.8.5"></a>

###### 3.1.3.8.5 Safety Results

No evidence found.

<a id="heading-3.1.3.9"></a>

##### 3.1.3.9 Study Limitations

<a id="topic-3.1.3.9-1"></a>

###### Summary

FORTIFI-FLEX is open-label, with no masking. Randomization occurs only after the 12-week loading phase and includes only participants without progression, so the randomized comparison addresses maintenance dosing in that subset. Both arms receive ficerafusp alfa with pembrolizumab. The primary endpoint, the proportion of maintenance-phase participants alive and progression-free at approximately 9 months, is assessed by BICR. Planned enrollment is 160 participants, and no results have been reported.

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163); [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="topic-3.1.3.9-2"></a>

###### Open-label design in the EU trial record

> “Multicenter, open-label, randomized Phase 2 study evaluating continuous weekly dosing of ficerafusp alfa (BCA101) in combination with pembrolizumab versus an alternative dosing regimen for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma”

Source: [EU CTIS 2026-526741-10-00](https://euclinicaltrials.eu/ctis-public-api/retrieve/2026-526741-10-00)

<a id="topic-3.1.3.9-3"></a>

###### Masking in the ClinicalTrials.gov record

> “Masking : None (Open Label)”

Source: [ClinicalTrials.gov NCT07807163](https://clinicaltrials.gov/study/NCT07807163)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
